Network meta-analysis

Level 2 or 3 hypoglycemia (participants)

Type 2 diabetes (adults)

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)

128

Randomized trials

Treatments

78,453

Participants

503

Events

In plain language

Across 128 trials with 78,453 participants, 8 of 42 treatments had a clearly better result than placebo on level 2 or 3 hypoglycemia (participants), and for 34 the evidence could not tell them apart from placebo. The most favorable estimate was for Polyethylene glycol loxenatide injection: hazard ratio (from event counts) 0.05 (95% credible interval 0.00 to 1.11).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Polyethylene glycol loxenatide injection PEGLOX_SC	0.05 (0.00 to 1.11)	0.00 to 2.24	Unclear
Exenatide extended release injection EXENER_SC	0.05 (0.00 to 0.94)	0.00 to 1.89	Better
Semaglutide tablet SEMA_PO	0.07 (0.00 to 2.29)	0.00 to 4.34	Unclear
Tirzepatide injection TIRZ_SC	0.07 (0.01 to 0.66)	0.00 to 1.89	Better
Metformin METFORMIN	0.08 (0.00 to 1.89)	0.00 to 4.10	Unclear
Premixed insulin INS_PREMIX	0.10 (0.00 to 3.66)	0.00 to 5.99	Unclear
Exenatide injection EXEN_SC	0.10 (0.01 to 0.47)	0.00 to 1.27	Better
Safiglipron (HRS-7535) tablet SAFIGL_PO	0.11 (0.00 to 4.02)	0.00 to 7.02	Unclear
Taspoglutide injection TASP_SC	0.11 (0.00 to 3.89)	0.00 to 7.23	Unclear
Sitagliptin SITAGLIPTIN	0.12 (0.02 to 0.51)	0.01 to 1.39	Better
Standard care or no added treatment STANDARD_CARE	0.13 (0.01 to 1.60)	0.00 to 3.66	Unclear
Insulin degludec INS_DEGLUDEC	0.15 (0.00 to 5.22)	0.00 to 9.69	Unclear
Dulaglutide injection DULA_SC	0.17 (0.04 to 0.53)	0.01 to 1.85	Better
Semaglutide injection SEMA_SC	0.17 (0.04 to 0.56)	0.01 to 2.11	Better
Dapagliflozin DAPAGLIFLOZIN	0.18 (0.00 to 9.49)	0.00 to 16.22	Unclear
Pioglitazone PIOGLITAZONE	0.22 (0.00 to 10.98)	0.00 to 21.15	Unclear
Liraglutide injection LIRA_SC	0.23 (0.05 to 0.76)	0.01 to 2.55	Better
Vildagliptin VILDAGLIPTIN	0.24 (0.00 to 12.24)	0.00 to 22.12	Unclear
Insulin glargine INS_GLARGINE	0.24 (0.06 to 0.74)	0.02 to 2.36	Better
Insulin glargine with lixisenatide injection IGLARLIXI_SC	0.25 (0.03 to 1.32)	0.01 to 3.50	Unclear
Visepegenatide injection VISEPE_SC	0.28 (0.00 to 14.14)	0.00 to 24.21	Unclear
Insulin icodec with semaglutide injection ICOSEMA_SC	0.31 (0.00 to 22.10)	0.00 to 32.88	Unclear
Insulin detemir INS_DETEMIR	0.31 (0.00 to 23.06)	0.00 to 34.43	Unclear
Insulin aspart (prandial) INS_ASPART	0.33 (0.03 to 3.42)	0.01 to 8.27	Unclear
Mazdutide injection MAZD_SC	0.33 (0.01 to 14.75)	0.00 to 30.28	Unclear
Danuglipron tablet DANU_PO	0.33 (0.00 to 25.32)	0.00 to 40.17	Unclear
Albiglutide injection ALBI_SC	0.34 (0.06 to 1.46)	0.02 to 4.76	Unclear
Sulfonylurea OTHER_ACTIVE_sulfonylurea	0.36 (0.00 to 23.99)	0.00 to 40.60	Unclear
Lixisenatide injection LIXI_SC	0.36 (0.08 to 1.28)	0.02 to 3.83	Unclear
PEG-loxenatide injection PEGYLA_SC	0.39 (0.00 to 27.27)	0.00 to 46.05	Unclear
Glibenclamide GLIBENCLAMIDE	0.40 (0.00 to 28.49)	0.00 to 50.10	Unclear
Additional oad OTHER_ACTIVE_additional_OAD	0.41 (0.01 to 25.34)	0.00 to 48.23	Unclear
Glimepiride GLIMEPIRIDE	0.42 (0.05 to 2.29)	0.01 to 5.87	Unclear
HRS-7535 tablet HRS7535_PO	0.42 (0.00 to 31.28)	0.00 to 51.35	Unclear
Efsubaglutide alfa injection EFSUBA_SC	0.48 (0.01 to 30.13)	0.00 to 53.20	Unclear
Cotadutide injection COTA_SC	0.57 (0.01 to 38.19)	0.00 to 64.99	Unclear
Insulin lispro (prandial) INS_LISPRO	0.62 (0.09 to 3.42)	0.03 to 9.66	Unclear
Insulin degludec with liraglutide injection IDEGLIRA_SC	0.74 (0.08 to 8.62)	0.03 to 19.87	Unclear
Investigator choice oral drug OTHER_ACTIVE_investigator_choice_oral_drug	1.20 (0.07 to 17.25)	0.03 to 37.73	Unclear
Efpe sc EFPE_SC	1.36 (0.05 to 54.49)	0.02 to 97.48	Unclear
Insulin dose increase OTHER_ACTIVE_insulin_dose_increase	2.68 (0.09 to 113)	0.04 to 236	Unclear
Basal bolus insulin OTHER_ACTIVE_basal_bolus_insulin	10.21 (0.48 to 230)	0.24 to 454	Unclear

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	PEGLOX_SC	EXENER_SC	SEMA_PO	TIRZ_SC	METFORMIN	INS_PREMIX	EXEN_SC	SAFIGL_PO	TASP_SC	SITAGLIPTIN	STANDARD_CARE	INS_DEGLUDEC	DULA_SC	SEMA_SC	DAPAGLIFLOZIN	PIOGLITAZONE	LIRA_SC	VILDAGLIPTIN	INS_GLARGINE	IGLARLIXI_SC	VISEPE_SC	ICOSEMA_SC	INS_DETEMIR	INS_ASPART	MAZD_SC	DANU_PO	ALBI_SC	OTHER_ACTIVE_sulfonylurea	LIXI_SC	PEGYLA_SC	GLIBENCLAMIDE	OTHER_ACTIVE_additional_OAD	GLIMEPIRIDE	HRS7535_PO	EFSUBA_SC	COTA_SC	INS_LISPRO	IDEGLIRA_SC	OTHER_ACTIVE_investigator_choice_oral_drug	EFPE_SC	OTHER_ACTIVE_insulin_dose_increase	OTHER_ACTIVE_basal_bolus_insulin
PLACEBO	PLACEBO	19.18 0.90 to 636	18.92 1.07 to 648	14.35 0.44 to 568	14.04 1.51 to 171	12.03 0.53 to 520	10.31 0.27 to 529	10.15 2.12 to 74.03	8.96 0.25 to 540	8.85 0.26 to 428	8.64 1.97 to 50.25	7.98 0.62 to 141	6.56 0.19 to 351	5.94 1.90 to 24.93	5.74 1.79 to 24.24	5.57 0.11 to 359	4.51 0.09 to 276	4.33 1.31 to 19.23	4.23 0.08 to 261	4.13 1.36 to 16.58	4.04 0.76 to 30.81	3.52 0.07 to 237	3.28 0.05 to 252	3.25 0.04 to 285	3.06 0.29 to 39.35	3.05 0.07 to 190	3.02 0.04 to 278	2.92 0.68 to 15.46	2.81 0.04 to 239	2.75 0.78 to 12.80	2.54 0.04 to 217	2.49 0.04 to 201	2.43 0.04 to 181	2.40 0.44 to 21.92	2.38 0.03 to 207	2.08 0.03 to 191	1.76 0.03 to 170	1.60 0.29 to 10.81	1.34 0.12 to 13.28	0.84 0.06 to 13.44	0.73 0.02 to 21.14	0.37 0.01 to 11.16	0.10 0.00 to 2.08
PEGLOX_SC	0.05 0.00 to 1.11	PEGLOX_SC	0.99 0.01 to 126	0.73 0.01 to 89.61	0.73 0.01 to 36.90	0.62 0.01 to 71.39	0.52 0.00 to 80.09	0.55 0.01 to 18.13	0.47 0.00 to 75.89	0.46 0.00 to 66.21	0.47 0.01 to 14.15	0.41 0.01 to 26.02	0.33 0.00 to 59.07	0.32 0.01 to 8.69	0.31 0.01 to 8.25	0.29 0.00 to 41.12	0.24 0.00 to 37.38	0.23 0.01 to 6.47	0.21 0.00 to 37.01	0.23 0.01 to 5.64	0.21 0.00 to 7.37	0.17 0.00 to 35.07	0.17 0.00 to 40.74	0.17 0.00 to 38.68	0.16 0.00 to 8.72	0.15 0.00 to 28.62	0.15 0.00 to 38.63	0.15 0.00 to 4.73	0.14 0.00 to 28.54	0.15 0.00 to 4.14	0.13 0.00 to 27.04	0.13 0.00 to 31.81	0.12 0.00 to 24.81	0.13 0.00 to 5.29	0.12 0.00 to 25.33	0.11 0.00 to 25.42	0.09 0.00 to 23.88	0.09 0.00 to 2.97	0.07 0.00 to 3.19	0.04 0.00 to 2.53	0.04 0.00 to 3.64	0.02 0.00 to 1.92	0.00 0.00 to 0.37
EXENER_SC	0.05 0.00 to 0.94	1.01 0.01 to 104	EXENER_SC	0.72 0.01 to 78.87	0.73 0.01 to 33.45	0.62 0.01 to 64.07	0.51 0.00 to 67.87	0.54 0.01 to 15.83	0.46 0.00 to 69.10	0.47 0.00 to 54.41	0.46 0.01 to 11.65	0.42 0.01 to 23.02	0.34 0.00 to 44.80	0.32 0.01 to 6.93	0.31 0.01 to 7.24	0.29 0.00 to 41.97	0.23 0.00 to 25.44	0.24 0.01 to 5.00	0.21 0.00 to 34.96	0.22 0.01 to 4.82	0.21 0.00 to 6.36	0.18 0.00 to 30.18	0.16 0.00 to 31.24	0.17 0.00 to 32.61	0.16 0.00 to 6.42	0.16 0.00 to 23.90	0.16 0.00 to 35.41	0.16 0.00 to 4.01	0.14 0.00 to 27.26	0.15 0.00 to 3.44	0.12 0.00 to 24.07	0.13 0.00 to 23.73	0.12 0.00 to 23.12	0.13 0.00 to 4.60	0.12 0.00 to 30.22	0.10 0.00 to 22.51	0.09 0.00 to 17.21	0.09 0.00 to 2.57	0.07 0.00 to 2.71	0.04 0.00 to 1.96	0.04 0.00 to 3.29	0.02 0.00 to 1.58	0.01 0.00 to 0.24
SEMA_PO	0.07 0.00 to 2.29	1.37 0.01 to 180	1.39 0.01 to 173	SEMA_PO	0.99 0.01 to 68.36	0.84 0.01 to 122	0.70 0.00 to 139	0.71 0.01 to 37.70	0.65 0.00 to 138	0.62 0.00 to 102	0.62 0.01 to 28.72	0.58 0.01 to 48.44	0.46 0.00 to 89.23	0.41 0.01 to 16.99	0.40 0.01 to 17.27	0.39 0.00 to 94.92	0.31 0.00 to 81.29	0.31 0.01 to 14.31	0.28 0.00 to 66.51	0.29 0.01 to 12.20	0.29 0.01 to 15.35	0.24 0.00 to 55.58	0.23 0.00 to 58.17	0.22 0.00 to 68.55	0.22 0.00 to 15.75	0.22 0.00 to 51.05	0.21 0.00 to 59.37	0.20 0.00 to 9.78	0.18 0.00 to 49.03	0.20 0.00 to 9.47	0.18 0.00 to 41.83	0.18 0.00 to 55.56	0.17 0.00 to 41.63	0.18 0.00 to 9.87	0.17 0.00 to 42.66	0.15 0.00 to 40.63	0.12 0.00 to 37.81	0.11 0.00 to 6.26	0.09 0.00 to 6.24	0.06 0.00 to 4.87	0.05 0.00 to 7.27	0.02 0.00 to 3.26	0.01 0.00 to 0.67
TIRZ_SC	0.07 0.01 to 0.66	1.37 0.03 to 85.04	1.37 0.03 to 85.82	1.01 0.01 to 84.39	TIRZ_SC	0.87 0.02 to 64.96	0.71 0.01 to 68.10	0.70 0.05 to 11.72	0.64 0.01 to 65.82	0.60 0.01 to 56.56	0.61 0.04 to 11.26	0.55 0.02 to 20.64	0.45 0.01 to 46.17	0.42 0.03 to 5.96	0.40 0.03 to 5.77	0.41 0.00 to 43.64	0.32 0.00 to 37.72	0.30 0.02 to 4.54	0.29 0.00 to 38.01	0.29 0.02 to 4.15	0.28 0.02 to 5.93	0.25 0.00 to 33.04	0.23 0.00 to 30.67	0.23 0.00 to 35.30	0.21 0.01 to 5.60	0.22 0.00 to 22.28	0.21 0.00 to 34.19	0.20 0.02 to 2.62	0.19 0.00 to 27.93	0.19 0.01 to 3.23	0.18 0.00 to 25.72	0.17 0.00 to 24.33	0.17 0.00 to 21.52	0.17 0.01 to 4.24	0.16 0.00 to 22.83	0.14 0.00 to 20.92	0.12 0.00 to 20.02	0.11 0.01 to 1.03	0.09 0.00 to 2.55	0.06 0.00 to 2.19	0.05 0.00 to 3.02	0.03 0.00 to 1.46	0.01 0.00 to 0.32
METFORMIN	0.08 0.00 to 1.89	1.60 0.01 to 147	1.60 0.02 to 173	1.19 0.01 to 159	1.15 0.02 to 65.09	METFORMIN	0.85 0.01 to 127	0.84 0.02 to 35.91	0.73 0.00 to 126	0.72 0.00 to 120	0.72 0.01 to 26.00	0.66 0.01 to 42.75	0.54 0.00 to 90.87	0.51 0.01 to 13.93	0.49 0.01 to 14.23	0.46 0.00 to 76.55	0.37 0.00 to 64.64	0.37 0.01 to 12.13	0.32 0.00 to 69.85	0.35 0.01 to 10.40	0.34 0.01 to 13.98	0.29 0.00 to 53.73	0.26 0.00 to 55.68	0.28 0.00 to 62.00	0.25 0.00 to 14.26	0.25 0.00 to 42.65	0.24 0.00 to 53.21	0.25 0.00 to 8.37	0.22 0.00 to 47.28	0.24 0.00 to 6.91	0.20 0.00 to 47.47	0.20 0.00 to 55.01	0.21 0.00 to 39.24	0.21 0.00 to 8.65	0.18 0.00 to 43.24	0.16 0.00 to 47.75	0.14 0.00 to 36.19	0.13 0.00 to 5.18	0.10 0.00 to 5.43	0.07 0.00 to 4.75	0.06 0.00 to 5.94	0.03 0.00 to 3.34	0.01 0.00 to 0.62
INS_PREMIX	0.10 0.00 to 3.66	1.91 0.01 to 283	1.94 0.01 to 262	1.43 0.01 to 222	1.40 0.01 to 107	1.18 0.01 to 189	INS_PREMIX	1.06 0.02 to 48.10	0.93 0.00 to 178	0.92 0.00 to 157	0.86 0.01 to 46.44	0.81 0.01 to 73.62	0.67 0.00 to 125	0.60 0.01 to 27.26	0.57 0.01 to 25.86	0.55 0.00 to 121	0.45 0.00 to 119	0.44 0.01 to 19.05	0.42 0.00 to 97.16	0.42 0.01 to 17.66	0.41 0.01 to 21.96	0.35 0.00 to 86.91	0.31 0.00 to 87.70	0.32 0.00 to 99.23	0.31 0.00 to 20.93	0.32 0.00 to 72.81	0.29 0.00 to 85.41	0.29 0.00 to 14.21	0.26 0.00 to 81.55	0.28 0.00 to 13.47	0.24 0.00 to 72.79	0.25 0.00 to 68.03	0.23 0.00 to 69.99	0.25 0.00 to 16.74	0.23 0.00 to 74.10	0.20 0.00 to 65.05	0.17 0.00 to 60.82	0.16 0.00 to 8.54	0.13 0.00 to 8.65	0.08 0.00 to 6.93	0.07 0.00 to 9.71	0.04 0.00 to 5.09	0.01 0.00 to 0.93
EXEN_SC	0.10 0.01 to 0.47	1.82 0.06 to 87.50	1.85 0.06 to 80.74	1.40 0.03 to 75.50	1.43 0.09 to 19.34	1.19 0.03 to 66.56	0.95 0.02 to 59.60	EXEN_SC	0.86 0.02 to 70.38	0.86 0.02 to 59.07	0.84 0.10 to 6.59	0.77 0.04 to 15.38	0.62 0.01 to 47.82	0.59 0.08 to 3.54	0.56 0.07 to 3.52	0.54 0.01 to 47.15	0.42 0.01 to 39.77	0.44 0.06 to 2.70	0.39 0.01 to 34.57	0.40 0.07 to 2.07	0.39 0.05 to 3.38	0.33 0.00 to 30.08	0.31 0.00 to 36.60	0.31 0.00 to 36.66	0.31 0.01 to 4.73	0.29 0.00 to 24.67	0.29 0.00 to 36.34	0.29 0.03 to 1.97	0.26 0.00 to 29.97	0.27 0.04 to 1.85	0.25 0.00 to 25.66	0.24 0.00 to 24.00	0.23 0.00 to 24.38	0.24 0.02 to 2.46	0.22 0.00 to 26.81	0.19 0.00 to 25.88	0.17 0.00 to 22.24	0.16 0.02 to 1.04	0.13 0.01 to 1.99	0.08 0.00 to 1.60	0.07 0.00 to 2.80	0.04 0.00 to 1.34	0.01 0.00 to 0.26
SAFIGL_PO	0.11 0.00 to 4.02	2.12 0.01 to 300	2.15 0.01 to 287	1.53 0.01 to 277	1.57 0.02 to 101	1.37 0.01 to 220	1.07 0.01 to 205	1.16 0.01 to 61.68	SAFIGL_PO	1.00 0.00 to 175	0.97 0.01 to 47.17	0.90 0.01 to 73.69	0.70 0.00 to 144	0.68 0.01 to 30.03	0.64 0.01 to 29.21	0.62 0.00 to 108	0.48 0.00 to 122	0.50 0.01 to 21.80	0.46 0.00 to 102	0.47 0.01 to 21.16	0.44 0.01 to 25.85	0.37 0.00 to 93.66	0.34 0.00 to 92.49	0.34 0.00 to 103	0.34 0.00 to 25.03	0.32 0.00 to 78.32	0.33 0.00 to 105	0.33 0.00 to 14.65	0.29 0.00 to 79.27	0.31 0.00 to 14.83	0.27 0.00 to 69.15	0.26 0.00 to 80.44	0.25 0.00 to 76.43	0.28 0.00 to 17.39	0.25 0.00 to 72.44	0.22 0.00 to 78.93	0.19 0.00 to 59.17	0.18 0.00 to 9.11	0.14 0.00 to 10.83	0.09 0.00 to 7.99	0.08 0.00 to 11.11	0.04 0.00 to 4.96	0.01 0.00 to 1.19
TASP_SC	0.11 0.00 to 3.89	2.16 0.02 to 267	2.13 0.02 to 304	1.61 0.01 to 244	1.66 0.02 to 116	1.38 0.01 to 211	1.09 0.01 to 218	1.17 0.02 to 58.16	1.00 0.01 to 222	TASP_SC	0.99 0.02 to 48.65	0.91 0.01 to 81.83	0.73 0.00 to 151	0.68 0.01 to 30.00	0.65 0.01 to 31.43	0.61 0.00 to 126	0.53 0.00 to 125	0.51 0.01 to 22.60	0.47 0.00 to 113	0.48 0.01 to 20.89	0.45 0.01 to 25.84	0.39 0.00 to 95.18	0.35 0.00 to 94.57	0.37 0.00 to 107	0.35 0.00 to 26.48	0.35 0.00 to 74.73	0.33 0.00 to 98.77	0.32 0.01 to 16.35	0.30 0.00 to 108	0.31 0.01 to 13.91	0.27 0.00 to 82.26	0.28 0.00 to 81.84	0.26 0.00 to 81.95	0.27 0.00 to 18.24	0.26 0.00 to 74.83	0.23 0.00 to 61.06	0.19 0.00 to 58.57	0.18 0.00 to 10.52	0.14 0.00 to 10.15	0.09 0.00 to 7.71	0.08 0.00 to 11.42	0.04 0.00 to 6.11	0.01 0.00 to 1.26
SITAGLIPTIN	0.12 0.02 to 0.51	2.15 0.07 to 103	2.15 0.09 to 93.65	1.62 0.03 to 83.03	1.64 0.09 to 26.27	1.39 0.04 to 73.60	1.16 0.02 to 82.20	1.19 0.15 to 10.05	1.03 0.02 to 76.01	1.01 0.02 to 60.00	SITAGLIPTIN	0.93 0.05 to 18.48	0.75 0.01 to 52.78	0.69 0.12 to 4.11	0.68 0.12 to 3.54	0.64 0.01 to 50.28	0.51 0.01 to 41.67	0.51 0.11 to 2.16	0.47 0.01 to 43.71	0.48 0.10 to 2.30	0.46 0.06 to 3.99	0.40 0.01 to 34.40	0.36 0.00 to 38.34	0.37 0.00 to 39.13	0.36 0.02 to 5.15	0.35 0.01 to 28.01	0.35 0.00 to 39.51	0.34 0.04 to 2.44	0.31 0.00 to 32.97	0.32 0.05 to 1.90	0.29 0.00 to 27.84	0.28 0.00 to 27.57	0.28 0.00 to 24.52	0.29 0.04 to 2.15	0.26 0.00 to 31.11	0.24 0.00 to 26.24	0.19 0.00 to 24.88	0.19 0.02 to 1.70	0.15 0.01 to 2.22	0.10 0.01 to 1.59	0.08 0.00 to 3.29	0.04 0.00 to 1.41	0.01 0.00 to 0.27
STANDARD_CARE	0.13 0.01 to 1.60	2.42 0.04 to 173	2.40 0.04 to 167	1.72 0.02 to 154	1.81 0.05 to 54.93	1.51 0.02 to 112	1.23 0.01 to 142	1.30 0.07 to 26.76	1.11 0.01 to 141	1.10 0.01 to 109	1.08 0.05 to 19.94	STANDARD_CARE	0.83 0.01 to 95.49	0.75 0.04 to 11.78	0.72 0.04 to 10.15	0.70 0.01 to 102	0.54 0.00 to 71.63	0.55 0.03 to 8.52	0.50 0.00 to 61.82	0.52 0.03 to 7.95	0.51 0.02 to 11.07	0.42 0.00 to 59.91	0.40 0.00 to 63.26	0.39 0.00 to 65.30	0.39 0.01 to 11.20	0.38 0.00 to 50.00	0.37 0.00 to 66.61	0.38 0.02 to 6.76	0.34 0.00 to 53.89	0.35 0.02 to 6.48	0.31 0.00 to 49.99	0.31 0.00 to 49.30	0.30 0.00 to 42.59	0.30 0.01 to 7.35	0.29 0.00 to 44.57	0.26 0.00 to 50.33	0.22 0.00 to 38.03	0.21 0.01 to 4.20	0.16 0.00 to 4.61	0.10 0.00 to 3.80	0.09 0.00 to 5.74	0.04 0.00 to 2.93	0.01 0.00 to 0.56
INS_DEGLUDEC	0.15 0.00 to 5.22	3.00 0.02 to 391	2.97 0.02 to 415	2.17 0.01 to 405	2.21 0.02 to 147	1.84 0.01 to 311	1.50 0.01 to 302	1.62 0.02 to 93.13	1.43 0.01 to 262	1.37 0.01 to 268	1.34 0.02 to 71.00	1.20 0.01 to 102	INS_DEGLUDEC	0.92 0.01 to 44.09	0.91 0.01 to 38.76	0.87 0.00 to 175	0.68 0.00 to 143	0.68 0.01 to 31.58	0.63 0.00 to 152	0.63 0.01 to 29.16	0.64 0.01 to 36.69	0.54 0.00 to 128	0.48 0.00 to 147	0.50 0.00 to 130	0.47 0.00 to 34.89	0.47 0.00 to 109	0.44 0.00 to 150	0.45 0.01 to 19.74	0.41 0.00 to 130	0.43 0.01 to 20.38	0.37 0.00 to 117	0.38 0.00 to 119	0.36 0.00 to 100	0.38 0.00 to 25.18	0.35 0.00 to 102	0.32 0.00 to 89.63	0.26 0.00 to 73.71	0.24 0.00 to 12.88	0.21 0.00 to 6.63	0.13 0.00 to 11.37	0.11 0.00 to 15.92	0.05 0.00 to 7.20	0.01 0.00 to 1.05
DULA_SC	0.17 0.04 to 0.53	3.17 0.12 to 125	3.11 0.14 to 124	2.44 0.06 to 105	2.39 0.17 to 33.34	1.97 0.07 to 89.99	1.66 0.04 to 95.57	1.69 0.28 to 12.35	1.47 0.03 to 104	1.48 0.03 to 77.77	1.45 0.24 to 8.65	1.34 0.08 to 24.90	1.08 0.02 to 73.54	DULA_SC	0.98 0.19 to 4.56	0.93 0.01 to 69.43	0.73 0.01 to 55.46	0.73 0.16 to 3.52	0.69 0.01 to 49.05	0.69 0.22 to 2.50	0.67 0.11 to 4.81	0.58 0.01 to 47.95	0.53 0.01 to 46.42	0.55 0.01 to 52.18	0.52 0.03 to 6.71	0.50 0.01 to 36.73	0.50 0.00 to 52.16	0.50 0.07 to 2.87	0.47 0.01 to 47.27	0.46 0.09 to 2.37	0.42 0.00 to 38.79	0.42 0.00 to 41.08	0.39 0.00 to 36.14	0.42 0.06 to 3.41	0.38 0.00 to 38.57	0.34 0.00 to 34.35	0.28 0.00 to 31.84	0.28 0.03 to 1.91	0.22 0.01 to 2.75	0.14 0.01 to 2.19	0.12 0.00 to 4.22	0.06 0.00 to 1.89	0.02 0.00 to 0.37
SEMA_SC	0.17 0.04 to 0.56	3.21 0.12 to 127	3.24 0.14 to 131	2.49 0.06 to 120	2.49 0.17 to 34.88	2.02 0.07 to 100	1.75 0.04 to 108	1.77 0.28 to 14.10	1.57 0.03 to 102	1.54 0.03 to 87.82	1.48 0.28 to 8.48	1.39 0.10 to 23.94	1.10 0.03 to 75.99	1.02 0.22 to 5.16	SEMA_SC	0.96 0.02 to 69.94	0.75 0.01 to 57.42	0.75 0.16 to 3.81	0.71 0.01 to 53.29	0.70 0.18 to 3.13	0.70 0.10 to 5.59	0.60 0.01 to 47.27	0.55 0.01 to 51.04	0.56 0.01 to 54.25	0.54 0.05 to 4.89	0.52 0.01 to 36.33	0.50 0.01 to 59.53	0.51 0.07 to 3.29	0.48 0.01 to 49.27	0.48 0.09 to 2.74	0.43 0.01 to 42.96	0.42 0.01 to 39.30	0.41 0.01 to 36.46	0.42 0.06 to 4.17	0.40 0.00 to 41.15	0.35 0.00 to 38.64	0.29 0.00 to 33.48	0.28 0.04 to 2.19	0.22 0.01 to 2.89	0.14 0.01 to 2.63	0.12 0.00 to 4.43	0.06 0.00 to 2.02	0.02 0.00 to 0.38
DAPAGLIFLOZIN	0.18 0.00 to 9.49	3.49 0.02 to 549	3.49 0.02 to 652	2.54 0.01 to 571	2.45 0.02 to 262	2.16 0.01 to 502	1.83 0.01 to 484	1.85 0.02 to 162	1.62 0.01 to 318	1.63 0.01 to 454	1.57 0.02 to 115	1.43 0.01 to 178	1.16 0.01 to 322	1.08 0.01 to 69.45	1.04 0.01 to 63.39	DAPAGLIFLOZIN	0.84 0.00 to 231	0.80 0.01 to 52.90	0.75 0.00 to 203	0.73 0.01 to 49.17	0.72 0.01 to 63.28	0.62 0.00 to 218	0.60 0.00 to 185	0.58 0.00 to 190	0.54 0.00 to 59.38	0.57 0.00 to 153	0.55 0.00 to 202	0.50 0.01 to 40.12	0.50 0.00 to 169	0.50 0.01 to 36.56	0.44 0.00 to 162	0.43 0.00 to 185	0.43 0.00 to 148	0.44 0.01 to 39.96	0.44 0.00 to 160	0.36 0.00 to 124	0.31 0.00 to 121	0.28 0.00 to 24.19	0.23 0.00 to 23.04	0.15 0.00 to 20.02	0.13 0.00 to 19.66	0.06 0.00 to 11.12	0.02 0.00 to 2.13
PIOGLITAZONE	0.22 0.00 to 10.98	4.18 0.03 to 895	4.41 0.04 to 620	3.26 0.01 to 746	3.12 0.03 to 310	2.74 0.02 to 512	2.24 0.01 to 632	2.37 0.03 to 189	2.07 0.01 to 507	1.87 0.01 to 467	1.95 0.02 to 132	1.84 0.01 to 224	1.48 0.01 to 389	1.36 0.02 to 86.48	1.34 0.02 to 82.55	1.19 0.00 to 366	PIOGLITAZONE	0.97 0.01 to 67.74	0.88 0.00 to 297	0.96 0.01 to 58.38	0.94 0.01 to 67.05	0.76 0.00 to 208	0.69 0.00 to 237	0.74 0.00 to 239	0.70 0.01 to 69.80	0.72 0.00 to 209	0.67 0.00 to 255	0.65 0.01 to 42.85	0.63 0.00 to 223	0.64 0.01 to 42.83	0.55 0.00 to 176	0.54 0.00 to 174	0.52 0.00 to 168	0.54 0.01 to 51.67	0.52 0.00 to 179	0.45 0.00 to 171	0.38 0.00 to 143	0.37 0.00 to 28.09	0.29 0.00 to 26.75	0.19 0.00 to 22.70	0.16 0.00 to 25.61	0.08 0.00 to 14.01	0.02 0.00 to 2.92
LIRA_SC	0.23 0.05 to 0.76	4.34 0.15 to 172	4.18 0.20 to 152	3.26 0.07 to 154	3.33 0.22 to 45.86	2.72 0.08 to 132	2.27 0.05 to 134	2.29 0.37 to 17.48	1.98 0.05 to 136	1.97 0.04 to 122	1.97 0.46 to 8.88	1.83 0.12 to 33.65	1.47 0.03 to 93.08	1.38 0.28 to 6.22	1.34 0.26 to 6.09	1.24 0.02 to 98.45	1.03 0.01 to 76.83	LIRA_SC	0.91 0.02 to 66.57	0.94 0.25 to 3.73	0.92 0.14 to 6.99	0.80 0.01 to 64.93	0.71 0.01 to 76.47	0.71 0.01 to 74.63	0.72 0.05 to 9.09	0.70 0.01 to 54.35	0.69 0.01 to 69.47	0.68 0.09 to 4.05	0.62 0.01 to 60.62	0.63 0.11 to 3.34	0.56 0.01 to 59.90	0.56 0.01 to 48.29	0.55 0.01 to 47.82	0.57 0.09 to 3.90	0.53 0.01 to 56.41	0.46 0.01 to 46.75	0.38 0.00 to 46.51	0.37 0.04 to 2.67	0.29 0.02 to 3.84	0.19 0.01 to 2.22	0.16 0.00 to 5.70	0.09 0.00 to 2.22	0.02 0.00 to 0.48
VILDAGLIPTIN	0.24 0.00 to 12.24	4.84 0.03 to 965	4.86 0.03 to 914	3.56 0.02 to 774	3.47 0.03 to 373	3.13 0.01 to 713	2.41 0.01 to 631	2.56 0.03 to 196	2.18 0.01 to 589	2.13 0.01 to 514	2.11 0.02 to 151	1.99 0.02 to 235	1.60 0.01 to 469	1.45 0.02 to 90.53	1.40 0.02 to 84.48	1.34 0.00 to 388	1.14 0.00 to 370	1.10 0.02 to 65.14	VILDAGLIPTIN	1.03 0.01 to 65.70	1.01 0.01 to 85.63	0.85 0.00 to 264	0.79 0.00 to 293	0.80 0.00 to 337	0.73 0.01 to 75.41	0.79 0.00 to 198	0.71 0.00 to 276	0.70 0.01 to 46.06	0.66 0.00 to 252	0.69 0.01 to 44.55	0.59 0.00 to 265	0.63 0.00 to 218	0.59 0.00 to 213	0.60 0.01 to 54.60	0.58 0.00 to 224	0.50 0.00 to 186	0.41 0.00 to 171	0.40 0.00 to 29.19	0.32 0.00 to 29.28	0.20 0.00 to 24.77	0.18 0.00 to 32.06	0.09 0.00 to 17.40	0.02 0.00 to 3.65
INS_GLARGINE	0.24 0.06 to 0.74	4.43 0.18 to 163	4.45 0.21 to 165	3.42 0.08 to 152	3.45 0.24 to 41.15	2.88 0.10 to 135	2.37 0.06 to 144	2.48 0.48 to 13.53	2.14 0.05 to 146	2.09 0.05 to 113	2.10 0.43 to 10.14	1.92 0.13 to 33.61	1.58 0.03 to 105	1.46 0.40 to 4.60	1.42 0.32 to 5.51	1.37 0.02 to 96.12	1.04 0.02 to 84.66	1.07 0.27 to 4.02	0.97 0.02 to 70.82	INS_GLARGINE	0.97 0.22 to 4.76	0.83 0.01 to 65.19	0.75 0.01 to 69.78	0.76 0.01 to 82.41	0.76 0.05 to 8.84	0.73 0.01 to 52.21	0.72 0.01 to 75.33	0.72 0.10 to 3.63	0.66 0.01 to 68.59	0.67 0.15 to 2.88	0.61 0.01 to 54.48	0.59 0.01 to 51.85	0.58 0.01 to 47.81	0.61 0.10 to 3.92	0.56 0.01 to 60.44	0.50 0.01 to 50.77	0.40 0.01 to 46.28	0.40 0.05 to 2.45	0.32 0.02 to 3.99	0.21 0.01 to 2.98	0.18 0.00 to 5.72	0.09 0.00 to 2.68	0.02 0.00 to 0.51
IGLARLIXI_SC	0.25 0.03 to 1.32	4.68 0.14 to 223	4.73 0.16 to 209	3.50 0.07 to 193	3.56 0.17 to 59.31	2.93 0.07 to 171	2.43 0.05 to 165	2.57 0.30 to 21.79	2.25 0.04 to 181	2.25 0.04 to 141	2.17 0.25 to 17.83	1.97 0.09 to 47.05	1.57 0.03 to 137	1.50 0.21 to 9.01	1.44 0.18 to 9.83	1.40 0.02 to 119	1.06 0.01 to 96.90	1.08 0.14 to 7.17	0.99 0.01 to 83.76	1.03 0.21 to 4.49	IGLARLIXI_SC	0.83 0.01 to 73.18	0.80 0.01 to 85.45	0.78 0.01 to 99.99	0.77 0.04 to 14.09	0.74 0.01 to 65.22	0.73 0.01 to 85.47	0.73 0.07 to 5.94	0.67 0.01 to 76.31	0.70 0.10 to 4.29	0.61 0.01 to 64.19	0.62 0.01 to 67.62	0.59 0.01 to 68.11	0.61 0.06 to 6.18	0.55 0.01 to 64.87	0.50 0.00 to 59.30	0.41 0.00 to 52.44	0.40 0.03 to 3.88	0.32 0.01 to 5.30	0.20 0.01 to 4.25	0.17 0.00 to 7.70	0.09 0.00 to 3.67	0.02 0.00 to 0.63
VISEPE_SC	0.28 0.00 to 14.14	5.76 0.03 to 1083	5.64 0.03 to 1061	4.11 0.02 to 923	4.08 0.03 to 413	3.51 0.02 to 715	2.90 0.01 to 799	3.03 0.03 to 220	2.70 0.01 to 700	2.59 0.01 to 699	2.51 0.03 to 173	2.37 0.02 to 269	1.84 0.01 to 441	1.74 0.02 to 117	1.66 0.02 to 101	1.62 0.00 to 418	1.32 0.00 to 363	1.25 0.02 to 79.16	1.18 0.00 to 305	1.20 0.02 to 73.02	1.21 0.01 to 89.80	VISEPE_SC	0.92 0.00 to 291	0.94 0.00 to 368	0.91 0.01 to 92.04	0.89 0.00 to 278	0.88 0.00 to 342	0.87 0.01 to 51.76	0.80 0.00 to 291	0.82 0.01 to 50.94	0.75 0.00 to 230	0.72 0.00 to 281	0.69 0.00 to 240	0.72 0.01 to 60.07	0.71 0.00 to 214	0.60 0.00 to 212	0.49 0.00 to 177	0.47 0.00 to 32.16	0.37 0.00 to 35.03	0.24 0.00 to 29.67	0.20 0.00 to 33.25	0.10 0.00 to 20.21	0.03 0.00 to 3.77
ICOSEMA_SC	0.31 0.00 to 22.10	6.02 0.02 to 1400	6.17 0.03 to 1380	4.42 0.02 to 1097	4.32 0.03 to 582	3.92 0.02 to 967	3.22 0.01 to 1092	3.19 0.03 to 336	2.97 0.01 to 1056	2.84 0.01 to 890	2.74 0.03 to 261	2.49 0.02 to 342	2.10 0.01 to 741	1.87 0.02 to 162	1.81 0.02 to 160	1.68 0.01 to 673	1.45 0.00 to 584	1.40 0.01 to 124	1.26 0.00 to 511	1.33 0.01 to 114	1.25 0.01 to 138	1.09 0.00 to 432	ICOSEMA_SC	1.01 0.00 to 473	0.95 0.01 to 116	1.01 0.00 to 349	0.94 0.00 to 422	0.92 0.01 to 89.49	0.90 0.00 to 385	0.88 0.01 to 82.91	0.79 0.00 to 356	0.77 0.00 to 371	0.74 0.00 to 330	0.78 0.01 to 80.56	0.74 0.00 to 388	0.65 0.00 to 265	0.54 0.00 to 315	0.50 0.00 to 52.35	0.40 0.00 to 55.29	0.25 0.00 to 46.57	0.22 0.00 to 48.17	0.11 0.00 to 28.81	0.03 0.00 to 5.61
INS_DETEMIR	0.31 0.00 to 23.06	6.00 0.03 to 1260	5.94 0.03 to 1231	4.57 0.01 to 1187	4.34 0.03 to 584	3.63 0.02 to 1004	3.15 0.01 to 1048	3.20 0.03 to 348	2.92 0.01 to 1105	2.72 0.01 to 905	2.71 0.03 to 298	2.58 0.02 to 431	2.00 0.01 to 765	1.83 0.02 to 169	1.78 0.02 to 172	1.73 0.01 to 547	1.35 0.00 to 535	1.41 0.01 to 135	1.26 0.00 to 492	1.32 0.01 to 119	1.28 0.01 to 151	1.06 0.00 to 420	0.99 0.00 to 458	INS_DETEMIR	0.94 0.01 to 132	0.92 0.00 to 389	0.92 0.00 to 429	0.90 0.01 to 91.56	0.85 0.00 to 382	0.87 0.01 to 86.36	0.77 0.00 to 321	0.75 0.00 to 364	0.76 0.00 to 311	0.77 0.01 to 89.51	0.71 0.00 to 342	0.64 0.00 to 263	0.53 0.00 to 276	0.51 0.00 to 55.15	0.39 0.00 to 59.52	0.25 0.00 to 44.35	0.21 0.00 to 52.36	0.11 0.00 to 28.91	0.03 0.00 to 6.15
INS_ASPART	0.33 0.03 to 3.42	6.23 0.11 to 396	6.23 0.16 to 422	4.61 0.06 to 348	4.65 0.18 to 125	3.95 0.07 to 317	3.26 0.05 to 306	3.20 0.21 to 69.63	2.98 0.04 to 302	2.87 0.04 to 278	2.75 0.19 to 52.21	2.56 0.09 to 90.61	2.14 0.03 to 216	1.93 0.15 to 29.56	1.85 0.20 to 18.94	1.86 0.02 to 211	1.44 0.01 to 190	1.39 0.11 to 21.87	1.36 0.01 to 157	1.32 0.11 to 20.37	1.30 0.07 to 28.20	1.10 0.01 to 145	1.05 0.01 to 150	1.06 0.01 to 148	INS_ASPART	1.01 0.01 to 112	0.99 0.01 to 162	0.95 0.05 to 17.31	0.90 0.01 to 146	0.90 0.07 to 14.15	0.82 0.01 to 123	0.79 0.01 to 131	0.80 0.01 to 107	0.78 0.05 to 21.81	0.73 0.01 to 121	0.68 0.00 to 112	0.56 0.00 to 95.40	0.53 0.03 to 10.94	0.43 0.01 to 11.79	0.27 0.01 to 11.31	0.23 0.00 to 15.36	0.12 0.00 to 7.31	0.03 0.00 to 1.34
MAZD_SC	0.33 0.01 to 14.75	6.53 0.03 to 1108	6.07 0.04 to 1065	4.55 0.02 to 1007	4.59 0.04 to 411	4.05 0.02 to 799	3.16 0.01 to 778	3.45 0.04 to 250	3.11 0.01 to 688	2.87 0.01 to 578	2.84 0.04 to 186	2.66 0.02 to 312	2.13 0.01 to 480	1.98 0.03 to 102	1.93 0.03 to 114	1.76 0.01 to 519	1.39 0.00 to 430	1.44 0.02 to 82.32	1.26 0.01 to 338	1.37 0.02 to 85.32	1.36 0.02 to 103	1.12 0.00 to 323	0.99 0.00 to 376	1.09 0.00 to 358	0.99 0.01 to 88.32	MAZD_SC	0.92 0.00 to 339	0.96 0.01 to 66.68	0.88 0.00 to 281	0.91 0.01 to 56.84	0.77 0.00 to 243	0.78 0.00 to 281	0.78 0.00 to 222	0.80 0.01 to 69.32	0.74 0.00 to 299	0.66 0.00 to 233	0.55 0.00 to 233	0.53 0.01 to 38.73	0.40 0.00 to 35.94	0.26 0.00 to 28.80	0.22 0.00 to 43.46	0.12 0.00 to 19.64	0.03 0.00 to 3.77
DANU_PO	0.33 0.00 to 25.32	6.76 0.03 to 1527	6.43 0.03 to 1486	4.80 0.02 to 1453	4.70 0.03 to 721	4.20 0.02 to 958	3.45 0.01 to 930	3.39 0.03 to 473	3.07 0.01 to 1092	3.01 0.01 to 1047	2.83 0.03 to 335	2.69 0.02 to 476	2.26 0.01 to 765	2.00 0.02 to 207	2.02 0.02 to 180	1.83 0.00 to 672	1.49 0.00 to 594	1.45 0.01 to 141	1.41 0.00 to 522	1.38 0.01 to 140	1.37 0.01 to 182	1.13 0.00 to 503	1.07 0.00 to 470	1.08 0.00 to 525	1.01 0.01 to 156	1.09 0.00 to 394	DANU_PO	0.97 0.01 to 111	0.93 0.00 to 436	0.92 0.01 to 96.97	0.81 0.00 to 434	0.84 0.00 to 408	0.80 0.00 to 353	0.81 0.01 to 110	0.77 0.00 to 398	0.68 0.00 to 373	0.61 0.00 to 298	0.55 0.00 to 64.85	0.43 0.00 to 55.04	0.27 0.00 to 48.09	0.23 0.00 to 57.17	0.12 0.00 to 30.30	0.03 0.00 to 5.98
ALBI_SC	0.34 0.06 to 1.46	6.50 0.21 to 274	6.44 0.25 to 280	4.92 0.10 to 257	4.88 0.38 to 66.59	4.07 0.12 to 206	3.42 0.07 to 213	3.40 0.51 to 32.86	3.08 0.07 to 245	3.10 0.06 to 184	2.91 0.41 to 27.05	2.66 0.15 to 65.28	2.20 0.05 to 164	1.99 0.35 to 14.18	1.97 0.30 to 14.21	1.98 0.02 to 152	1.54 0.02 to 123	1.46 0.25 to 11.62	1.44 0.02 to 114	1.39 0.28 to 9.57	1.36 0.17 to 14.47	1.16 0.02 to 107	1.09 0.01 to 108	1.11 0.01 to 118	1.05 0.06 to 18.60	1.05 0.01 to 86.46	1.03 0.01 to 120	ALBI_SC	0.94 0.01 to 90.38	0.93 0.14 to 7.27	0.87 0.01 to 86.62	0.87 0.01 to 89.35	0.81 0.01 to 78.67	0.81 0.09 to 10.55	0.80 0.01 to 89.77	0.73 0.01 to 79.49	0.60 0.01 to 73.19	0.55 0.09 to 3.51	0.44 0.02 to 6.54	0.28 0.01 to 6.42	0.24 0.00 to 9.07	0.13 0.00 to 4.73	0.03 0.00 to 0.88
OTHER_ACTIVE_sulfonylurea	0.36 0.00 to 23.99	6.97 0.04 to 1555	7.05 0.04 to 1515	5.59 0.02 to 1265	5.23 0.04 to 682	4.55 0.02 to 1148	3.84 0.01 to 1107	3.79 0.03 to 386	3.47 0.01 to 952	3.34 0.01 to 1071	3.25 0.03 to 297	2.96 0.02 to 442	2.44 0.01 to 726	2.15 0.02 to 184	2.07 0.02 to 188	1.98 0.01 to 765	1.59 0.00 to 669	1.60 0.02 to 123	1.51 0.00 to 464	1.52 0.01 to 124	1.48 0.01 to 159	1.25 0.00 to 454	1.11 0.00 to 517	1.17 0.00 to 577	1.12 0.01 to 161	1.13 0.00 to 427	1.08 0.00 to 459	1.06 0.01 to 94.40	OTHER_ACTIVE_sulfonylurea	1.02 0.01 to 80.62	0.86 0.00 to 436	0.90 0.00 to 370	0.86 0.00 to 342	0.88 0.01 to 102	0.82 0.00 to 348	0.75 0.00 to 358	0.62 0.00 to 372	0.58 0.00 to 60.06	0.47 0.00 to 56.19	0.28 0.00 to 42.13	0.25 0.00 to 60.64	0.13 0.00 to 26.66	0.03 0.00 to 6.12
LIXI_SC	0.36 0.08 to 1.28	6.71 0.24 to 282	6.75 0.29 to 279	5.07 0.11 to 248	5.16 0.31 to 76.08	4.24 0.14 to 205	3.62 0.07 to 232	3.70 0.54 to 27.62	3.27 0.07 to 222	3.18 0.07 to 191	3.09 0.53 to 21.04	2.83 0.15 to 57.08	2.35 0.05 to 156	2.15 0.42 to 10.63	2.08 0.36 to 11.43	2.01 0.03 to 142	1.57 0.02 to 115	1.58 0.30 to 8.86	1.45 0.02 to 115	1.49 0.35 to 6.59	1.44 0.23 to 10.13	1.22 0.02 to 108	1.13 0.01 to 115	1.14 0.01 to 130	1.11 0.07 to 15.15	1.10 0.02 to 74.55	1.09 0.01 to 116	1.08 0.14 to 6.93	0.98 0.01 to 100	LIXI_SC	0.88 0.01 to 94.96	0.88 0.01 to 89.57	0.87 0.01 to 77.35	0.89 0.11 to 7.92	0.83 0.01 to 87.23	0.70 0.01 to 79.66	0.62 0.01 to 70.53	0.59 0.06 to 4.66	0.47 0.03 to 6.50	0.29 0.02 to 5.25	0.26 0.00 to 9.08	0.13 0.00 to 4.37	0.04 0.00 to 0.81
PEGYLA_SC	0.39 0.00 to 27.27	7.57 0.04 to 1864	8.03 0.04 to 1659	5.66 0.02 to 1550	5.57 0.04 to 819	4.94 0.02 to 1226	4.23 0.01 to 1198	4.08 0.04 to 491	3.66 0.01 to 1267	3.68 0.01 to 1064	3.45 0.04 to 301	3.24 0.02 to 482	2.67 0.01 to 768	2.39 0.03 to 209	2.31 0.02 to 197	2.26 0.01 to 771	1.83 0.01 to 655	1.77 0.02 to 152	1.70 0.00 to 612	1.64 0.02 to 150	1.64 0.02 to 191	1.34 0.00 to 591	1.26 0.00 to 533	1.29 0.00 to 654	1.21 0.01 to 164	1.31 0.00 to 340	1.23 0.00 to 524	1.15 0.01 to 99.38	1.16 0.00 to 457	1.13 0.01 to 96.06	PEGYLA_SC	1.03 0.00 to 403	0.92 0.00 to 428	0.99 0.01 to 108	0.94 0.00 to 462	0.82 0.00 to 321	0.70 0.00 to 374	0.63 0.01 to 66.72	0.51 0.00 to 60.86	0.32 0.00 to 49.70	0.28 0.00 to 59.81	0.14 0.00 to 33.44	0.04 0.00 to 6.65
GLIBENCLAMIDE	0.40 0.00 to 28.49	7.49 0.03 to 1983	7.55 0.04 to 1747	5.65 0.02 to 1555	5.79 0.04 to 670	4.99 0.02 to 1356	3.96 0.01 to 1251	4.10 0.04 to 436	3.82 0.01 to 1242	3.61 0.01 to 1107	3.53 0.04 to 338	3.19 0.02 to 492	2.66 0.01 to 937	2.38 0.02 to 216	2.40 0.03 to 196	2.35 0.01 to 799	1.86 0.01 to 656	1.77 0.02 to 152	1.60 0.00 to 648	1.69 0.02 to 139	1.62 0.01 to 174	1.39 0.00 to 647	1.30 0.00 to 543	1.34 0.00 to 712	1.26 0.01 to 163	1.28 0.00 to 456	1.19 0.00 to 627	1.15 0.01 to 115	1.11 0.00 to 466	1.14 0.01 to 96.13	0.97 0.00 to 431	GLIBENCLAMIDE	0.93 0.00 to 413	1.01 0.01 to 104	0.92 0.00 to 417	0.86 0.00 to 398	0.71 0.00 to 326	0.67 0.01 to 63.11	0.50 0.00 to 70.94	0.32 0.00 to 50.66	0.28 0.00 to 60.09	0.14 0.00 to 33.02	0.04 0.00 to 6.01
OTHER_ACTIVE_additional_OAD	0.41 0.01 to 25.34	8.16 0.04 to 1935	8.18 0.04 to 1855	5.72 0.02 to 1831	5.92 0.05 to 772	4.83 0.03 to 1442	4.26 0.01 to 1429	4.41 0.04 to 469	4.00 0.01 to 1081	3.86 0.01 to 1059	3.55 0.04 to 318	3.39 0.02 to 470	2.77 0.01 to 736	2.56 0.03 to 203	2.43 0.03 to 185	2.31 0.01 to 805	1.92 0.01 to 721	1.81 0.02 to 149	1.70 0.00 to 606	1.74 0.02 to 139	1.69 0.01 to 178	1.44 0.00 to 558	1.35 0.00 to 566	1.32 0.00 to 580	1.24 0.01 to 173	1.29 0.00 to 397	1.25 0.00 to 525	1.23 0.01 to 112	1.17 0.00 to 518	1.15 0.01 to 95.16	1.08 0.00 to 433	1.08 0.00 to 434	OTHER_ACTIVE_additional_OAD	1.02 0.01 to 121	0.97 0.00 to 475	0.87 0.00 to 402	0.75 0.00 to 298	0.66 0.01 to 69.66	0.55 0.00 to 61.51	0.34 0.00 to 46.09	0.29 0.00 to 62.75	0.15 0.00 to 33.55	0.04 0.00 to 7.90
GLIMEPIRIDE	0.42 0.05 to 2.29	7.85 0.19 to 339	7.63 0.22 to 339	5.65 0.10 to 340	5.83 0.24 to 100	4.81 0.12 to 304	4.07 0.06 to 290	4.14 0.41 to 41.17	3.59 0.06 to 292	3.68 0.05 to 252	3.47 0.47 to 26.14	3.28 0.14 to 75.84	2.61 0.04 to 217	2.39 0.29 to 17.45	2.37 0.24 to 17.68	2.27 0.03 to 183	1.85 0.02 to 155	1.76 0.26 to 11.39	1.66 0.02 to 154	1.65 0.26 to 10.42	1.64 0.16 to 15.53	1.39 0.02 to 144	1.28 0.01 to 139	1.30 0.01 to 164	1.28 0.05 to 22.13	1.24 0.01 to 105	1.23 0.01 to 142	1.23 0.09 to 10.68	1.13 0.01 to 124	1.12 0.13 to 9.23	1.01 0.01 to 118	0.99 0.01 to 106	0.98 0.01 to 105	GLIMEPIRIDE	0.94 0.01 to 116	0.83 0.01 to 105	0.67 0.01 to 89.20	0.66 0.05 to 6.89	0.52 0.02 to 8.66	0.33 0.01 to 6.89	0.29 0.00 to 11.80	0.15 0.00 to 6.09	0.04 0.00 to 1.17
HRS7535_PO	0.42 0.00 to 31.28	8.09 0.04 to 2046	8.50 0.03 to 2066	6.05 0.02 to 1629	6.19 0.04 to 813	5.45 0.02 to 1162	4.34 0.01 to 1385	4.51 0.04 to 420	3.97 0.01 to 1205	3.84 0.01 to 1298	3.77 0.03 to 341	3.50 0.02 to 522	2.88 0.01 to 896	2.63 0.03 to 207	2.52 0.02 to 219	2.27 0.01 to 912	1.93 0.01 to 754	1.88 0.02 to 157	1.72 0.00 to 710	1.78 0.02 to 153	1.80 0.02 to 182	1.41 0.00 to 639	1.35 0.00 to 574	1.40 0.00 to 570	1.37 0.01 to 191	1.36 0.00 to 609	1.30 0.00 to 612	1.26 0.01 to 126	1.22 0.00 to 499	1.20 0.01 to 101	1.06 0.00 to 491	1.08 0.00 to 497	1.03 0.00 to 455	1.07 0.01 to 114	HRS7535_PO	0.89 0.00 to 403	0.75 0.00 to 381	0.69 0.01 to 70.85	0.55 0.00 to 69.70	0.37 0.00 to 49.50	0.29 0.00 to 69.40	0.16 0.00 to 36.57	0.04 0.00 to 7.72
EFSUBA_SC	0.48 0.01 to 30.13	9.17 0.04 to 2249	9.54 0.04 to 2081	6.73 0.02 to 1890	7.02 0.05 to 814	6.32 0.02 to 1404	4.95 0.02 to 1689	5.17 0.04 to 517	4.51 0.01 to 1571	4.26 0.02 to 1451	4.13 0.04 to 412	3.88 0.02 to 554	3.15 0.01 to 969	2.92 0.03 to 254	2.85 0.03 to 229	2.74 0.01 to 906	2.24 0.01 to 720	2.18 0.02 to 179	2.02 0.01 to 690	2.01 0.02 to 161	1.99 0.02 to 206	1.68 0.00 to 648	1.53 0.00 to 641	1.57 0.00 to 694	1.47 0.01 to 202	1.50 0.00 to 576	1.47 0.00 to 641	1.37 0.01 to 114	1.33 0.00 to 521	1.42 0.01 to 117	1.22 0.00 to 417	1.17 0.00 to 647	1.15 0.00 to 483	1.21 0.01 to 134	1.13 0.00 to 488	EFSUBA_SC	0.86 0.00 to 434	0.79 0.01 to 74.99	0.61 0.00 to 74.54	0.39 0.00 to 65.19	0.34 0.00 to 68.71	0.18 0.00 to 34.29	0.05 0.00 to 7.45
COTA_SC	0.57 0.01 to 38.19	11.47 0.04 to 2567	11.42 0.06 to 2570	8.36 0.03 to 2327	8.24 0.05 to 1062	6.92 0.03 to 1811	5.97 0.02 to 1982	6.01 0.04 to 626	5.29 0.02 to 1829	5.26 0.02 to 1730	5.13 0.04 to 485	4.64 0.03 to 784	3.82 0.01 to 1262	3.52 0.03 to 299	3.40 0.03 to 288	3.20 0.01 to 1084	2.61 0.01 to 948	2.62 0.02 to 226	2.41 0.01 to 832	2.47 0.02 to 197	2.47 0.02 to 239	2.02 0.01 to 753	1.84 0.00 to 824	1.87 0.00 to 924	1.79 0.01 to 239	1.83 0.00 to 776	1.64 0.00 to 709	1.67 0.01 to 155	1.63 0.00 to 758	1.62 0.01 to 142	1.44 0.00 to 639	1.41 0.00 to 725	1.34 0.00 to 620	1.50 0.01 to 174	1.33 0.00 to 627	1.17 0.00 to 653	COTA_SC	0.95 0.01 to 91.93	0.71 0.00 to 96.53	0.48 0.00 to 71.75	0.40 0.00 to 92.29	0.21 0.00 to 46.64	0.05 0.00 to 10.64
INS_LISPRO	0.62 0.09 to 3.42	11.31 0.34 to 563	11.73 0.39 to 538	8.82 0.16 to 538	8.84 0.97 to 76.39	7.54 0.19 to 425	6.30 0.12 to 404	6.23 0.96 to 52.31	5.43 0.11 to 450	5.49 0.10 to 360	5.22 0.59 to 55.82	4.82 0.24 to 124	4.09 0.08 to 315	3.61 0.52 to 28.76	3.58 0.46 to 28.34	3.58 0.04 to 277	2.69 0.04 to 251	2.70 0.37 to 23.41	2.51 0.03 to 235	2.53 0.41 to 19.15	2.47 0.26 to 29.00	2.14 0.03 to 207	1.99 0.02 to 221	1.98 0.02 to 226	1.90 0.09 to 37.01	1.90 0.03 to 170	1.83 0.02 to 228	1.81 0.29 to 10.67	1.72 0.02 to 213	1.71 0.21 to 15.55	1.58 0.01 to 175	1.50 0.02 to 172	1.51 0.01 to 157	1.52 0.15 to 19.79	1.45 0.01 to 158	1.27 0.01 to 156	1.06 0.01 to 143	INS_LISPRO	0.80 0.04 to 14.12	0.51 0.02 to 13.34	0.44 0.01 to 18.83	0.22 0.00 to 9.49	0.06 0.00 to 1.84
IDEGLIRA_SC	0.74 0.08 to 8.62	15.12 0.31 to 1037	14.86 0.37 to 924	11.27 0.16 to 872	11.10 0.39 to 328	9.63 0.18 to 785	7.74 0.12 to 846	7.92 0.50 to 174	7.31 0.09 to 732	6.94 0.10 to 693	6.63 0.45 to 131	6.19 0.22 to 245	4.81 0.15 to 375	4.56 0.36 to 75.27	4.53 0.35 to 72.42	4.35 0.04 to 500	3.51 0.04 to 461	3.41 0.26 to 59.23	3.14 0.03 to 382	3.16 0.25 to 53.57	3.10 0.19 to 71.22	2.71 0.03 to 352	2.47 0.02 to 360	2.55 0.02 to 364	2.35 0.08 to 78.42	2.48 0.03 to 295	2.35 0.02 to 340	2.25 0.15 to 41.74	2.12 0.02 to 338	2.11 0.15 to 38.82	1.95 0.02 to 329	2.00 0.01 to 294	1.80 0.02 to 253	1.91 0.12 to 44.52	1.82 0.01 to 274	1.64 0.01 to 247	1.40 0.01 to 200	1.25 0.07 to 26.44	IDEGLIRA_SC	0.63 0.02 to 24.54	0.56 0.01 to 36.85	0.29 0.00 to 18.72	0.08 0.00 to 1.27
OTHER_ACTIVE_investigator_choice_oral_drug	1.20 0.07 to 17.25	23.36 0.40 to 1995	23.19 0.51 to 1757	17.33 0.21 to 1585	17.15 0.46 to 627	14.81 0.21 to 1373	12.38 0.14 to 1318	12.36 0.62 to 313	11.22 0.13 to 1351	10.79 0.13 to 1132	10.46 0.63 to 199	9.92 0.26 to 427	7.94 0.09 to 920	7.10 0.46 to 131	7.06 0.38 to 131	6.79 0.05 to 861	5.38 0.04 to 785	5.29 0.45 to 73.99	4.93 0.04 to 615	4.87 0.34 to 89.76	4.94 0.24 to 125	4.23 0.03 to 663	3.94 0.02 to 690	4.05 0.02 to 704	3.77 0.09 to 128	3.81 0.03 to 460	3.71 0.02 to 736	3.51 0.16 to 70.87	3.54 0.02 to 553	3.40 0.19 to 66.08	3.14 0.02 to 503	3.09 0.02 to 565	2.93 0.02 to 479	3.02 0.15 to 70.53	2.73 0.02 to 517	2.55 0.02 to 415	2.08 0.01 to 435	1.96 0.07 to 49.49	1.59 0.04 to 46.53	OTHER_ACTIVE_investigator_choice_oral_drug	0.87 0.01 to 59.34	0.46 0.00 to 26.67	0.11 0.00 to 6.69
EFPE_SC	1.36 0.05 to 54.49	28.00 0.27 to 4292	27.11 0.30 to 3958	21.28 0.14 to 3379	20.43 0.33 to 1866	18.05 0.17 to 3036	14.36 0.10 to 2821	14.27 0.36 to 968	13.24 0.09 to 3111	12.72 0.09 to 2605	12.34 0.30 to 724	11.34 0.17 to 1116	9.31 0.06 to 2153	8.41 0.24 to 418	8.23 0.23 to 428	7.73 0.05 to 1940	6.42 0.04 to 1609	6.11 0.18 to 333	5.62 0.03 to 1711	5.70 0.17 to 303	5.76 0.13 to 386	4.94 0.03 to 1343	4.59 0.02 to 1254	4.71 0.02 to 1440	4.39 0.07 to 402	4.47 0.02 to 1232	4.30 0.02 to 1446	4.11 0.11 to 238	4.06 0.02 to 1097	3.80 0.11 to 214	3.54 0.02 to 1066	3.60 0.02 to 1142	3.48 0.02 to 1041	3.41 0.08 to 242	3.41 0.01 to 1042	2.97 0.01 to 1011	2.50 0.01 to 945	2.25 0.05 to 159	1.79 0.03 to 147	1.15 0.02 to 128	EFPE_SC	0.50 0.00 to 81.68	0.14 0.00 to 17.98
OTHER_ACTIVE_insulin_dose_increase	2.68 0.09 to 113	53.76 0.52 to 8829	54.70 0.63 to 8142	40.47 0.31 to 6520	38.77 0.69 to 3010	34.96 0.30 to 6613	27.55 0.20 to 5913	27.86 0.74 to 1780	26.13 0.20 to 6150	25.09 0.16 to 5342	23.62 0.71 to 1294	22.23 0.34 to 2099	18.31 0.14 to 3934	15.99 0.53 to 809	15.85 0.50 to 803	15.71 0.09 to 3603	12.86 0.07 to 3364	11.46 0.45 to 568	11.46 0.06 to 3168	11.22 0.37 to 573	10.80 0.27 to 751	9.73 0.05 to 2494	8.83 0.03 to 2621	9.35 0.03 to 2997	8.41 0.14 to 680	8.46 0.05 to 2255	8.25 0.03 to 2499	7.79 0.21 to 423	7.92 0.04 to 2295	7.66 0.23 to 427	7.08 0.03 to 2229	7.03 0.03 to 1851	6.55 0.03 to 1848	6.64 0.16 to 443	6.31 0.03 to 2152	5.65 0.03 to 1647	4.86 0.02 to 1679	4.46 0.11 to 270	3.47 0.05 to 282	2.18 0.04 to 216	1.98 0.01 to 292	OTHER_ACTIVE_insulin_dose_increase	0.25 0.00 to 33.52
OTHER_ACTIVE_basal_bolus_insulin	10.21 0.48 to 230	207 2.68 to 26524	195 4.13 to 19191	154 1.48 to 17293	153 3.15 to 6826	134 1.63 to 14970	105 1.07 to 15311	106 3.88 to 3835	98.81 0.84 to 16768	95.79 0.79 to 12529	90.26 3.67 to 2682	85.01 1.78 to 5441	68.78 0.96 to 8443	60.66 2.72 to 1769	60.37 2.65 to 1716	60.63 0.47 to 9725	46.32 0.34 to 7690	45.38 2.08 to 1301	42.92 0.27 to 7761	42.65 1.96 to 1103	42.48 1.59 to 1541	36.37 0.27 to 5784	32.73 0.18 to 6833	35.29 0.16 to 7509	32.52 0.75 to 1625	33.28 0.27 to 4827	30.84 0.17 to 6383	30.47 1.14 to 973	29.07 0.16 to 6584	28.51 1.23 to 829	26.40 0.15 to 5393	25.53 0.17 to 5619	24.73 0.13 to 5116	26.01 0.85 to 961	25.14 0.13 to 5252	21.81 0.13 to 4392	18.47 0.09 to 3891	17.04 0.54 to 573	12.74 0.79 to 293	8.74 0.15 to 517	7.38 0.06 to 808	3.94 0.03 to 353	OTHER_ACTIVE_basal_bolus_insulin

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 1.057 (95% CrI 0.478 to 1.807), log scale
Residual deviance: 138.8 for 271 data points
DIC: 200.4 (pD 61.5)
Largest R-hat: 1.003
Smallest ESS: bulk 850, tail 1,415
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-2.1, 1.58^2) on tau^2 (Adverse events, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Baseline HbA1c (percent) effect modifier, prognostic factor; 127 of 128	Background glucose lowering therapy (stratum S0 to S4) effect modifier, prognostic factor; 125 of 128
GETGOAL-L-ASIA S000488	8.53	S2
GETGOAL-S S000491	8.26	S1
AMPLITUDE-M S002081	8.07	S0
SUSTAIN™ S002082	8.13	S0
NCT02449603 S001146	8.78	S1
AWARD-9 S000446	8.4	S2
SUSTAIN 9 S000483	8.05	S1
NCT03131687 S000010	8.13	S1
NCT00754988 S000027	7.96	S1
NCT02325960 S000058	8.18	S1
NCT01296412 S000080	8.15	S1
NCT00838916 S000099	8.31	S1
SURPASS-6 S000108	8.8	S2
NCT04965506 S000140	8.05	S4
MAGNA VICTORIA S000142	8.37	S4
REWIND S000147	7.35	S4
COMBINE 2 S000155	8	S1
SCALE™ Insulin S000159	7.95	S2
STEP HFpEF DM S000161	6.8 median	S4
DUAL™IV S000164	7.9	S1
Lixilan-O-AP S000170	8.34	S1
NCT01476475 S000191	8.05	S1
OUTSTAND-1 S000213	7.95	S0
PB119 S000217	8.5	S0
NCT01001104 S000232	8.02	S0
PIONEER 10 S000234	8.31	S1
AWARD-7 S000237	8.6	S3
NCT01584232 S000246	8.05	S1
AWARD-10 S000305	8.04	S1
NCT00393718 S000330	9.27	S0
EGO S000337	8.24	S1
NCT00765817 S000345	8.4	S2
NCT01029886 S000352	8.45	S1
SUSTAIN 11 S000363	8.55	S2
NCT00791479 S000376	7.24	S0
REMODEL S000395	7.03	S4
NCT00637273 S000402	8.53	S1
NCT00976937 S000415	8.13	S1
NCT00516074 S000435	7.31	S1
NCT00082407 S000441	8.6	S1
LIRA-PRIME S000508	8.15	S1
PIONEER 12 S000522	8.12	S1
NCT03596450 S000545	not reported	S1
NCT06589765 S000558	8.6	S1
NCT00960661 S000609	8.25	S2
PREVAIL S000693	6.57	S2
NCT02229383 S000703	8.53	S2
NCT00577824 S000752	8.22	S1
NCT01149421 S000784	7.93	S1
NCT01558271 S000837	8.14	S0
NCT00849017 S000852	8.07	S0
NCT00395746 S000862	8.82	S1
GRADE S000873	7.5	S1
NCT05759897 S000877	8.52	S1
SUSTAIN™1 S000878	8.05	S0
GetGoal-O S000904	8.04	S4
NCT01617434 S000926	8.25	S2
LIRA-Ramadan™ S000963	8.25	S1
NCT02200991 S001003	8.29	S2
AWARD-CHN1 S001064	7.97	S0
AWARD-8 S001068	8.4	S1
NCT02465515 S001074	8.7	S4
LIRA-SWITCH™ S001119	8.25	S1
DURATION-NEO-2 S001157	8.45	S1
NCT05514535 S001161	7.9	S2
AWARD-6 S001184	8.05	S1
GetGoal-M-Asia S001185	7.9	S1
NCT03985293 S001191	8.08	S1
NCT01191268 S001198	8.46	S3
LixiLan-O S001199	8.1	S1
GETGOAL-P S001204	8.07	S1
NCT04504396 S001230	8.47	S1
NCT00877890 S001308	8.45	S1
SUSTAIN S001311	8.1	S1
NCT00360334 S001323	8.57	S1
NCT01003184 S001355	8.36	S1
SOLID-DKD S001370	7.61	S4
AWARD-CHN2 S001404	8.37	S1
LixiLan-L S001409	8.08	S2
GETGOAL-X S001439	7.96	S1
NCT00299871 S001455	7.55	S1
SUSTAIN™ S001498	8.06	S4
LEAD-2 S001502	8.38	S1
DUAL™ II China S001556	8.94	S2
GETGOAL-F1 S001563	8.04	S1
NCT00460941 S001597	7.9	S1
NCT03322631 S001634	7.99	S0
NCT00744926 S001638	7.7	S0
NCT00971659 S001719	8.06	S2
ELEGANT S001780	7.34	S4
NCT01126580 S001786	7.6	S0
PIONEER 11 S001791	7.95	S0
SUSTAIN™ 5 S001872	8.37	S2
SUSTAIN™ 2 S001876	8.07	S1
NCT02229227 S001887	7.7	S3
AGAC2 S001949	10.54	S3
NCT01632163 S001963	7.9	S2
NCT00676338 S001966	8.53	S0
LIXILAN JP-O1 S002018	8.39	S1
GETGOAL-L S002023	8.4	S2
NCT02887625 S002035	10	S1
NCT03550378 S002039	7.86	S4
LEAD-5 S002098	8.26	S1
Lixilan-L-CN S002110	8.3	S2
NCT05767255 S002117	11.6	S0
NCT04998032 S002121	8.66	S1
GETGOAL-M S002188	8.05	S1
NCT01425580 S002231	13.83 median	S1
NCT03311724 S002256	8.38	S1
NCT04466904 S002331	8.7	S4
GETGOAL-MONO S002333	8.03	S0
NCT02113332 S002357	9	S3
NCT00700817 S002361	8.43	S1
NCT03520972 S002761	8.68	S0
S002928 S002928	7.3 median	S1
S002951 S002951	8.75	not reported
S002984 S002984	8.67	S1
S003009 S003009	8.31	S4
S003030 S003030	8.5	S1
S003047 S003047	8.35	S1
S003050 S003050	7.15	S1
S003058 S003058	7.85 median	S2
S003070 S003070	10.8 median	S3
S003071 S003071	7.8	S1
S003072 S003072	8	not reported
S003079 S003079	9.26	S3
S003094 S003094	8.74	S4
S003437 S003437	7.84	not reported

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Baseline HbA1c: design means range from 6.6 (EXEN_SC vs INS_LISPRO vs STANDARD_CARE) to 13.8 (GLIMEPIRIDE vs LIRA_SC) percent; threshold 0.5
FlagEligibility, hba1c entry range: a design requires hba1c 1000 or more while another admits only 7.5 or less
FlagEligibility, bmi entry range: a design requires bmi 50 or more while another admits only 30 or less
NoteOutcome assessment, time point: selected time points span 0.43 to 386.13 weeks
NoteOutcome assessment, analysis set: mixed: completers 5, full_analysis 7, modified_itt 13, other 4, per_protocol 1, randomized 8, safety 90
NoteOutcome assessment, definition: mixed: ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms 1, ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms 1, ADA severe hypoglycemia 2, adjudicated severe hypoglycemia while on assigned medication;measured glucose below 54 mg/dL in 30 days before any quarterly visit 1, confirmed: severe or plasma glucose below 3.1 mmol/L 2, documented below 3.0 mmol/L regardless of symptoms (ADA level 2) 1, documented plasma glucose below 3.0 mmol/L regardless of symptoms 1, glucose below 3.0 mmol/L; no severe events in any arm 1, glucose below 54 mg/dL or severe hypoglycemia 1, Grade 3, needing third party assistance 1, hypoglycemia below 3.0 mmol/L or requiring assistance 1, hypoglycemia leading to admission or emergency visit 1, hypoglycemia requiring medical assistance 1, hypoglycemia requiring third party assistance 1, level 3 severe hypoglycemia 2, major hypoglycemia 1, Major hypoglycemia needing third party assistance or with loss of consciousness 1, major hypoglycemia, subject unable to self treat 1, major, unable to self treat 1, Major: loss of consciousness or seizure, or glucose below 3.0 mmol/L needing assistance;Minor confirmed: symptoms with glucose below 3.0 mmol/L, self treated 1, minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia 1, minor hypoglycemia, plasma glucose below 3.1 mmol/L 1, minor: symptomatic, glucose below 3.0 mmol/L, not major 1, minor: symptoms with glucose below 3 mmol/L, self treated or resolved 1, minor: symptoms with glucose below 3.0 mmol/L, self treated 1, not stated 39, participants whose worst on therapy event had glucose below 3.1 mmol/L 1, plasma glucose 54 mg/dL or lower 1, protocol defined severe hypoglycemia 1, severe (ADA) or blood glucose confirmed below 3.1 mmol/L with symptoms 1, severe hypoglycemia 10, Severe hypoglycemia 1, severe hypoglycemia by ADA classification 2, Severe hypoglycemia needing another person to give carbohydrate, glucagon or other measures (protocol) 1, severe hypoglycemia needing assistance 1, Severe hypoglycemia needing assistance 1, severe hypoglycemia needing assistance of another person 4, Severe hypoglycemia needing assistance with glucose below 36 mg/dL or prompt recovery 1, severe hypoglycemia needing emergency care 1, severe hypoglycemia needing medical assistance 1, Severe hypoglycemia needing medical treatment 1, severe hypoglycemia needing resuscitative help, before rescue 1, severe hypoglycemia needing third party assistance 1, severe hypoglycemia requiring assistance from another person 2, Severe hypoglycemia requiring assistance of another person 2, severe hypoglycemia requiring third party assistance 1, Severe hypoglycemia requiring third party assistance 1, severe hypoglycemia with severe cognitive impairment needing medical treatment 1, severe hypoglycemia, subject unable to treat self 1, severe hypoglycemia, undefined 4, severe hypoglycemic events, adverse event of special interest 1, severe or BG confirmed symptomatic below 3.1 mmol/L 1, severe or plasma glucose confirmed below 3.1 mmol/L 1, severe symptomatic hypoglycemia 2, Severe symptomatic hypoglycemia 1, severe symptomatic hypoglycemia needing assistance 3, severe symptomatic hypoglycemia needing assistance of another person, glucose below 2.0 mmol/L or prompt recovery 1, severe symptomatic hypoglycemia requiring assistance of another person 1, severe symptomatic hypoglycemia requiring assistance, glucose below 2.0 mmol/L or prompt recovery 1, severe symptomatic hypoglycemia requiring third party assistance 1, severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery 1, severe, assistance of another person required 1, severe, needing assistance of another person 1, severe, requiring assistance of another person 2, severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery 1
NoteOutcome assessment, adjudicated: mixed: not stated 127, yes 1
NoteOutcome assessment, proportion method: mixed: not stated 122, observed 6
NoteOutcome assessment, intercurrent events (discontinuation): mixed: hypothetical 2, not stated 123, treatment_policy 1, while_on_treatment 2
NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 11, not stated 116, treatment_policy 1
NoteRisk of bias, blinding: mixed: double_blind 71, not_reported 2, open_label 50, single_blind 5
NoteRisk of bias, funding: mixed: industry 107, mixed 9, non_industry 11, not_reported 1
NoteData handling, input conversions: arms_combined 46, count_from_percent 5, printed_denominator 17

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
GETGOAL-L-ASIA	24	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
GETGOAL-S	120	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults on sulfonylurea with or without metformin; HbA1c 7 to 10 percent
AMPLITUDE-M	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months
SUSTAIN™	35	safety	severe hypoglycemia by ADA classification	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise
NCT02449603	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2015	age 18 to 70, HbA1c 7.5 to 10.0 percent on metformin at least 1500 mg, BMI 21 to 35
AWARD-9	28	safety	not stated	not stated	not stated	observed	not stated	hypothetical	double_blind	industry	2014	adults with T2D on basal insulin glargine with or without metformin
SUSTAIN 9	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU
NCT03131687	30	safety	severe hypoglycemia needing assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT00754988	156	safety	severe hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg
NCT02325960	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2015	age 18 to 70; BMI 24 or more; HbA1c 7.0 to 10.0 percent; metformin 1.5 g/day or more
NCT01296412	26	safety	severe hypoglycemia needing medical assistance	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	age 18 to 79; HbA1c 7.0 to 11.0 percent on metformin 1500 mg or more; eGFR 60 or more
NCT00838916	52	safety	severe hypoglycemia needing resuscitative help, before rescue	not stated	not stated	not stated	not stated	hypothetical	open_label	industry	2009	age 18 or older, HbA1c 7.0 to 10.0 percent, BMI 20 to 45, creatinine clearance above 60
SURPASS-6	56	safety	glucose below 54 mg/dL or severe hypoglycemia	not stated	not stated	not stated	while_on_treatment	hypothetical	open_label	industry	2020	adults 18 or older; HbA1c 7.5 to 11 percent; BMI 23 to 45; basal insulin at least 30 U/day with or without up to 2 oral drugs
NCT04965506	24	safety	glucose below 3.0 mmol/L; no severe events in any arm	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 20 to under 40; diet or metformin
MAGNA VICTORIA	26	safety	severe hypoglycemia, undefined	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2015	South Asian descent; age 18 to 74; BMI 23 or more; HbA1c 6.5 to 11.0 percent
REWIND	365.26	randomized	Severe hypoglycemia needing another person to give carbohydrate, glucagon or other measures (protocol)	not stated	not stated	not stated	treatment_policy	not stated	double_blind	industry	2011	age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors
COMBINE 2	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults T2D on GLP-1 RA with or without oral drugs; HbA1c 7.0 to 10.0 percent
SCALE™ Insulin	58	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 27 or higher; HbA1c 6.0 to 10 percent; basal insulin plus up to 2 oral drugs
STEP HFpEF DM	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 or older; heart failure with LVEF 45% or more; BMI 30 or more; type 2 diabetes with HbA1c 10% or less
DUAL™IV	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	adults 18 or older; HbA1c 7.0 to 9.0 percent; BMI 40 or less; SU with or without metformin; insulin and GLP-1 RA naive
Lixilan-O-AP	24.43	safety	documented plasma glucose below 3.0 mmol/L regardless of symptoms	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	adults with T2D on metformin with or without a second OAD; HbA1c 7.5 to 11 percent, or 7 to 10 percent with a non SGLT2i second OAD
NCT01476475	24	safety	Severe symptomatic hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive
OUTSTAND-1	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 19.0 to 40.0; diet and exercise only
PB119	24	safety	Severe hypoglycemia needing medical treatment	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; HbA1c 7.5 to 11.0 at screening and 7.0 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or more; drug naive
NCT01001104	12	safety	severe hypoglycemia needing assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in
PIONEER 10	57	safety	severe (ADA) or blood glucose confirmed below 3.1 mmol/L with symptoms	not stated	not stated	not stated	while_on_treatment	treatment_policy	single_blind	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
AWARD-7	52	safety	severe hypoglycemia needing assistance of another person	not stated	not stated	not stated	hypothetical	hypothetical	single_blind	industry	2012	adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45
NCT01584232	26	safety	severe, needing assistance of another person	not stated	not stated	not stated	not stated	hypothetical	open_label	industry	2012	Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide
AWARD-10	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2015	T2D; HbA1c 7.0 to 9.5 percent; BMI 45 or lower; SGLT2i with or without metformin
NCT00393718	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 or older; HbA1c 7.4 to 10.4 percent NGSP; with or without prior oral agents
EGO	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	overweight or obese adults with type 2 diabetes
NCT00765817	30	full_analysis	minor: symptoms with glucose below 3 mmol/L, self treated or resolved	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults 18 or older; insulin glargine 20 U/d or more alone or with metformin or pioglitazone; HbA1c 7.1 to 10.5 percent; BMI 45 or less
NCT01029886	26	modified_itt	Major hypoglycemia needing third party assistance or with loss of consciousness	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	adults 18 or older with type 2 diabetes on oral agents, HbA1c 7.1 to 11.0 percent, BMI 45 or less
SUSTAIN 11	52	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	adults; HbA1c above 7.5 to 10.0 percent on insulin glargine plus metformin
NCT00791479	12	modified_itt	severe hypoglycemia	not stated	not stated	not stated	not stated	hypothetical	double_blind	industry	2008	adults with type 2 diabetes on no background glucose lowering drug
REMODEL	57	randomized	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	T2D with HbA1c 9.0 percent or less; eGFR 30 to 75; UACR 20 to under 5000 mg/g
NCT00637273	26	modified_itt	not stated	not stated	not stated	observed	not stated	not stated	double_blind	industry	2008	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; stable metformin
NCT00976937	24	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 to under 50; BMI 30 or more; HbA1c 7.0 to 10 percent; metformin at least 1.5 g/day
NCT00516074	12	modified_itt	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; metformin and/or thiazolidinedione
NCT00082407	52	modified_itt	Severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2003	Age 30 to 75; HbA1c 7.0 to 11.0 on metformin plus sulfonylurea; BMI 25 to 40
LIRA-PRIME	104	safety	severe or BG confirmed symptomatic below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	adults; HbA1c 7.5 to 9.0 percent; stable metformin monotherapy
PIONEER 12	31	safety	ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	adults with type 2 diabetes on metformin, HbA1c 7.0 to 10.5 percent
NCT03596450	104.36	randomized	hypoglycemia leading to admission or emergency visit	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	adults with type 2 diabetes on metformin, later up to 2 oral drugs, needing intensification
NCT06589765	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more
NCT00960661	30	other	minor: symptoms with glucose below 3.0 mmol/L, self treated	not stated	not stated	observed	not stated	not stated	open_label	industry	2009	age 18 or older; T2D on insulin glargine and metformin with or without sulfonylurea; HbA1c 7.0 to 10.0; BMI 25.0 (23.0 in South Korea) to 45.0; HbA1c above 7.0 after optimization
PREVAIL	20	modified_itt	severe hypoglycemia, undefined	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2014	age 30 to 80; T2D 7 years or less; A1c 6.0 to 9.5 percent off drugs or 5.5 to 9.0 on up to 2 oral drugs
NCT02229383	38	safety	minor: symptomatic, glucose below 3.0 mmol/L, not major	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	adults; insulin glargine 20 U/d or more with or without metformin; HbA1c 7.0 to 10.5 percent at randomization
NCT00577824	24	full_analysis	Severe hypoglycemia requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 20 to 75; HbA1c 7.0 to 10.0 percent JDS; weight 50 kg or more; sulfonylurea based oral therapy
NCT01149421	26	safety	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	adults 18 or older; HbA1c 7 to 9.5 percent; stable oral agents
NCT01558271	52	safety	severe, assistance of another person required	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
NCT00849017	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 or older; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; diet and exercise only
NCT00395746	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 or older; HbA1c 7.4 to 10.4 on one sulfonylurea
GRADE	386.13	per_protocol	adjudicated severe hypoglycemia while on assigned medication;measured glucose below 54 mg/dL in 30 days before any quarterly visit	not stated	yes	not stated	hypothetical	hypothetical	single_blind	mixed	2013	age at diagnosis 30 or older; T2D under 10 years; HbA1c 6.8 to 8.5 percent; metformin 1000 mg/day or more
NCT05759897	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	age 18 to 75; BMI 19.0 to 40.0; HbA1c 7.5 to 11.0 on stable metformin
SUSTAIN™1	35	safety	severe hypoglycemia by ADA classification	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; drug naive on diet and exercise; eGFR 30 or more
GetGoal-O	24.43	safety	severe symptomatic hypoglycemia	not stated	not stated	observed	not stated	not stated	double_blind	industry	2013	age 70 or older; type 2 diabetes uncontrolled on basal insulin and/or oral drugs; eGFR 30 or higher
NCT01617434	27	safety	severe hypoglycemia, subject unable to treat self	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 to 80; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; basal insulin analogue 20 U or more with or without metformin
LIRA-Ramadan™	30	safety	confirmed: severe or plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 80; HbA1c 7 to 10 percent; BMI 20 or more; metformin plus sulfonylurea; intent to fast in Ramadan
NCT02200991	4.43	safety	severe hypoglycemia needing third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine
AWARD-CHN1	26	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
AWARD-8	24	modified_itt	severe hypoglycemia needing assistance of another person	not stated	not stated	not stated	not stated	hypothetical	double_blind	industry	2013	age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose
NCT02465515	140.89	safety	severe hypoglycemic events, adverse event of special interest	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2015	type 2 diabetes with established cardiovascular disease
LIRA-SWITCH™	27	safety	confirmed: severe or plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 18 or more; HbA1c 7.5 to 9.5 percent; BMI 20 or more; on sitagliptin 100 mg and metformin for 90 days or more
DURATION-NEO-2	28	safety	minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 45 or lower; metformin 1500 mg or more
NCT05514535	45	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
AWARD-6	26	modified_itt	severe hypoglycemia	not stated	not stated	observed	not stated	hypothetical	open_label	industry	2012	adults; HbA1c 7 to 10 percent; metformin 1500 mg/day or more
GetGoal-M-Asia	24	safety	severe symptomatic hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	Asian adults with type 2 diabetes on metformin with or without sulfonylurea
NCT03985293	20	safety	protocol defined severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise
NCT01191268	52	safety	not stated	not stated	not stated	not stated	not stated	hypothetical	open_label	industry	2010	adults with type 2 diabetes on conventional insulin with or without metformin
LixiLan-O	30.14	safety	severe symptomatic hypoglycemia requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	adults; HbA1c 7.5 to 10% on metformin or 7 to 9% on metformin plus second OAD; 7 to 10% after run in
GETGOAL-P	132	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	type 2 diabetes on pioglitazone 30 mg or more with or without metformin; HbA1c 7 percent or more
NCT04504396	24	safety	severe hypoglycemia with severe cognitive impairment needing medical treatment	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 40 or lower; eGFR 60 or higher; metformin monotherapy at least 1000 mg
NCT00877890	24	modified_itt	major hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45
SUSTAIN	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more
NCT00360334	26	full_analysis	severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	open_label	industry	2006	BMI above 27; HbA1c 7.5 to 10.0 percent; 2 or 3 oral drugs; at least one CV risk factor
NCT01003184	26	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; HbA1c 7.1 to 10.0 percent; BMI 25 to 45; metformin with or without SU
SOLID-DKD	18	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; T2D with UACR 300 to below 3000 mg/g; eGFR 30 or more; HbA1c 6.5 to 10; BMI 20 to 40
AWARD-CHN2	52	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
LixiLan-L	30	safety	severe symptomatic hypoglycemia requiring third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	adults with T2D on basal insulin 15 to 40 U/d; HbA1c 7 to 10% and glargine 20 to 50 U after run in
GETGOAL-X	116	safety	severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day
NCT00299871	13.43	safety	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 30 to 75; HbA1c 7.0 to below 9.0 percent on metformin at least 1000 mg/day
SUSTAIN™	62	safety	ADA severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese adults 20 or older; HbA1c 7.0 to 10.5 percent; diet and exercise or OAD monotherapy; eGFR 30 or more
LEAD-2	104	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 18 to 80; HbA1c 7 to 11 percent on one OAD or 7 to 10 on combination; BMI 40 or less; no recent insulin
DUAL™ II China	26	safety	severe or plasma glucose confirmed below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 24 or higher; HbA1c 7.5 or higher; basal insulin 20 to 50 U plus metformin
GETGOAL-F1	112	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults with T2D on metformin
NCT00460941	12	safety	severe hypoglycemia, undefined	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; HbA1c 7.0 to 9.5 percent on metformin; BMI above 25 to 45
NCT03322631	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Japanese adults 20 to 70; T2D 1 year or more on diet or metformin or DPP-4 inhibitor (washed out); BMI 20 to 35
NCT00744926	24	safety	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 80; drug naive; HbA1c 6.5 to 10 percent; BMI 25 to 45
NCT00971659	4	modified_itt	major hypoglycemia, subject unable to self treat	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 35 to 70; T2D 6 months to 10 years; HbA1c 7 to 10 percent; BMI 21 to 39.9
ELEGANT	26	randomized	Grade 3, needing third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 to 75; BMI 25 or more; HbA1c 6.5 to 8.5 percent; insulin 3 to 16 months with 4 percent weight gain
NCT01126580	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	type 2 diabetes on diet and exercise or one oral drug; registry gives no ranges
PIONEER 11	31	safety	ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more
SUSTAIN™ 5	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
SUSTAIN™ 2	56	safety	ADA severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	type 2 diabetes on metformin and or thiazolidinedione; HbA1c 7.0 to 10.5 percent
NCT02229227	26	safety	participants whose worst on therapy event had glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 75; HbA1c 7.0 to 9.5 percent at screening; BMI 40 or less; basal plus prandial insulin
AGAC2	0.43	randomized	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2011	age over 20, T2DM over 2 years, A1C 8 to 12 percent, premixed insulin twice daily over 0.6 U/kg/day
NCT01632163	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	adults; T2D at least 1 year; HbA1c 7 to 10.5 at screening, 7 to 9.5 after run in; basal insulin at least 15 U
NCT00676338	26	full_analysis	Major: loss of consciousness or seizure, or glucose below 3.0 mmol/L needing assistance;Minor confirmed: symptoms with glucose below 3.0 mmol/L, self treated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults, HbA1c 7.1 to 11.0 percent, BMI 23 to 45 kg/m2, drug naive
LIXILAN JP-O1	52.14	safety	severe hypoglycemia requiring assistance from another person	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs
GETGOAL-L	125	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults; HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin
NCT02887625	78.21	other	severe hypoglycemia requiring third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2015	age 18 to 75; HbA1c above 7.5 percent on near maximal metformin plus sulfonylurea
NCT03550378	8.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	age 18 to 84; BMI 25 to 45; eGFR 30 to 59; HbA1c 6.5 to 10.5 percent
LEAD-5	26	safety	minor hypoglycemia, plasma glucose below 3.1 mmol/L	not stated	not stated	observed	not stated	not stated	double_blind	industry	2006	age 18 to 80; HbA1c 7.5 to 10 on monotherapy or 7 to 10 on combination; BMI 45 or lower
Lixilan-L-CN	30	safety	documented below 3.0 mmol/L regardless of symptoms (ADA level 2)	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L
NCT05767255	4	modified_itt	Severe hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2022	adults hospitalized with T2D needing MDI; HbA1c 8.0 to 15 percent; eGFR 15 or more
NCT04998032	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; metformin monotherapy; HbA1c 7.5 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or higher
GETGOAL-M	76.43	safety	severe symptomatic hypoglycemia needing assistance of another person, glucose below 2.0 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less
NCT01425580	18	other	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	mixed	2012	type 2 diabetes; HbA1c 45 to 97 mmol/mol; subclinical LV dysfunction on echocardiography; BMI 40 or less
NCT03311724	16	modified_itt	plasma glucose 54 mg/dL or lower	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
NCT04466904	20	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; T2D on diet and exercise or stable metformin; HbA1c 7.5 to 11.0 percent; BMI 20 to 35
GETGOAL-MONO	12.43	safety	severe symptomatic hypoglycemia requiring assistance, glucose below 2.0 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 20 to 85; HbA1c 7.0 to 10.0 percent; no glucose lowering drug for 3 months
NCT02113332	24	full_analysis	Severe hypoglycemia requiring assistance of another person	not stated	not stated	not stated	not stated	hypothetical	double_blind	industry	2013	T2D on multiple daily insulin injections; HbA1c 7.5 to 11.5 percent; BMI 27.5 to 45 kg/m2
NCT00700817	52	other	major, unable to self treat	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 to 80; HbA1c 7.5 to 10%; BMI 45 or less; metformin 1500 mg/day or more for 3 months
NCT03520972	12	safety	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2018	age 18 to 70; BMI 18.5 to 35; HbA1c 7.5 to 11.0 percent; drug naive 3 months on diet and exercise
S002928	24	safety	hypoglycemia below 3.0 mmol/L or requiring assistance	not stated	not stated	not stated	not stated	not stated	single_blind	non_industry	2022	age 18 to 65; BMI 50 or more; type 2 diabetes
S002951	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2022	age 18 to 65; BMI 25 or more; HbA1c 7.0 to 10.0 percent; lifestyle or one OAD
S002984	24	randomized	severe hypoglycemia requiring assistance from another person	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2020	T2D age 45 or older; HbA1c 7.0 to 11.0 percent; metformin at least 3 months
S003009	24	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2023	age 18 or more; HbA1c 7.0 to 10.0 percent; eGFR 30 to 90; UACR above 30 to 5000 mg/g
S003030	52	full_analysis	severe hypoglycemia, undefined	not stated	not stated	not stated	not stated	not stated	open_label	industry	2015	age 20 to 75; HbA1c 7.5 to 11 percent; two or more oral agents for 3 months
S003047	6.57	safety	Severe hypoglycemia needing assistance with glucose below 36 mg/dL or prompt recovery	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 to 75; HbA1c 7.0 to 10.0 percent; BMI 35 or less; sulfonylurea with or without metformin
S003050	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	not_reported	non_industry	2020	age 18 to 65; diabetes 2 years or less, no ASCVD; HbA1c 7.0 to 7.5 percent; BMI 18.5 to 30; metformin 1000 mg
S003058	12	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry		age 20 to 90; HbA1c 7.0 to 10.0 percent; on insulin glargine plus sitagliptin 50 mg at least 8 weeks
S003070	2	completers	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	not_reported		newly diagnosed hospitalized T2D; age 25 to 70; HbA1c 9 to 14 percent; BMI 25 to 35
S003071	24	randomized	hypoglycemia requiring third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to under 80; HbA1c 6.9 to 9.4 percent NGSP; BMI 35 or less; on sulfonylurea
S003072	14	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2011	age 20 to 80; HbA1c above 6.9 percent on sitagliptin 50 mg for 3 months or more
S003079	5	safety	hypoglycemia requiring medical assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months
S003094	12	completers	Severe hypoglycemia requiring third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2011	HbA1c 7.5 to 11%; BMI 25 or more; waist 90 cm men, 85 cm women; insulin 10 U/day or more for 3 months
S003437	24	randomized	severe hypoglycemia needing emergency care	not stated	not stated	not stated	not stated	not stated	not_reported	non_industry	2025	knee osteoarthritis Kellgren Lawrence I to III; obesity; metabolic syndrome; type 2 diabetes for randomized groups

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT03131687	A1	PLACEBO	30	arm, events	0 / 51		R0016215:Table 3
NCT03131687	A2+A3+A4+A5	TIRZ_SC	30	arm, events	0 / 213	arms_combined	R0016215:Table 3
NCT03131687	A6	DULA_SC	30	arm, events	0 / 54		R0016215:Table 3
NCT00754988	A2+A3	TASP_SC	156	arm, events	0 / 388	arms_combined	R0022521:Abstract
NCT00754988	A4	SITAGLIPTIN	156	arm, events	0 / 185		R0022521:Abstract
NCT02325960	A1	EXEN_SC	16	arm, events	0 / 22		R0024438:Results
NCT02325960	A2	INS_GLARGINE	16	arm, events	0 / 23		R0024438:Results
NCT01296412	A1	SITAGLIPTIN	26	arm, events	1 / 326		R0026295:Results
NCT01296412	A2	LIRA_SC	26	arm, events	1 / 327		R0026295:Results
NCT00838916	A1	ALBI_SC	52	arm, events	2 / 516		R0025374:Table 3
NCT00838916	A2	INS_GLARGINE	52	arm, events	1 / 263		R0025374:Table 3
SURPASS-6	A1+A2+A3	TIRZ_SC	56	arm, events	3 / 717	arms_combined	R0009666:Table 4
SURPASS-6	A4	INS_LISPRO	56	arm, events	30 / 711		R0009666:Table 4
NCT04965506	A1+A2+A3	MAZD_SC	24	arm, events	0 / 149	arms_combined	R0012443:Table 2
NCT04965506	A4	DULA_SC	24	arm, events	0 / 50		R0012443:Table 2
NCT04965506	A5	PLACEBO	24	arm, events	0 / 51		R0012443:Table 2
MAGNA VICTORIA	A1	LIRA_SC	26	arm, events	0 / 22		R0021697:Results
MAGNA VICTORIA	A2	PLACEBO	26	arm, events	0 / 25		R0021697:Results
REWIND	A1	PLACEBO	365.26	arm, events	74 / 4,952		R0018537:Table 3
REWIND	A2	DULA_SC	365.26	arm, events	64 / 4,949		R0018537:Table 3
COMBINE 2	A1	ICOSEMA_SC	57	arm, events	0 / 342		R0005851:Table 4
COMBINE 2	A2	SEMA_SC	57	arm, events	0 / 341		R0005851:Table 4
SCALE™ Insulin	A1	LIRA_SC	58	arm, events	3 / 198		R0024063:Table 3
SCALE™ Insulin	A2	PLACEBO	58	arm, events	2 / 198		R0024063:Table 3
STEP HFpEF DM	A1	SEMA_SC	57	arm, events	5 / 310		R0018972:Table 4
STEP HFpEF DM	A2	PLACEBO	57	arm, events	4 / 306		R0018972:Table 4
DUAL™IV	A1	IDEGLIRA_SC	27	arm, events	2 / 289		R0015199:Table 2
DUAL™IV	A2	PLACEBO	27	arm, events	0 / 146		R0015199:Table 2
Lixilan-O-AP	A1	IGLARLIXI_SC	24.43	arm, events	1 / 351		R0013321:Table 3
Lixilan-O-AP	A2	INS_GLARGINE	24.43	arm, events	1 / 350		R0013321:Table 3
Lixilan-O-AP	A3	LIXI_SC	24.43	arm, events	1 / 177		R0013321:Table 3
NCT01476475	A1	IGLARLIXI_SC	24	arm, events	0 / 161		R0021236:p5
NCT01476475	A2	INS_GLARGINE	24	arm, events	0 / 162		R0021236:p5
OUTSTAND-1	A1+A2+A3	SAFIGL_PO	32	arm, events	0 / 212	arms_combined	R0011607:Table 3
OUTSTAND-1	A4	PLACEBO	32	arm, events	0 / 72		R0011607:Table 3
PB119	A1	VISEPE_SC	24	arm, events	0 / 137		R0011471:Table 4
PB119	A2	PLACEBO	24	arm, events	0 / 136		R0011471:Table 4
NCT01001104	A1	PLACEBO	12	arm, events	0 / 37		R0015000:Results
NCT01001104	A2+A3+A4	DULA_SC	12	arm, events	0 / 108	arms_combined	R0015000:Results
PIONEER 10	A1+A2+A3	SEMA_PO	57	arm, events	0 / 393	arms_combined	R0018421:Table 3
PIONEER 10	A4	DULA_SC	57	arm, events	0 / 65		R0018421:Table 3
AWARD-7	A1	INS_GLARGINE	52	arm, events	13 / 194		R0017387:Results
AWARD-7	A2+A3	DULA_SC	52	arm, events	5 / 383	arms_combined	R0017387:Results
NCT01584232	A1	DULA_SC	26	arm, events	0 / 181		R0016159:Results
NCT01584232	A2	INS_GLARGINE	26	arm, events	0 / 180		R0016159:Results
AWARD-10	A1+A2	DULA_SC	24	arm, events	1 / 284	arms_combined	R0020348:p1
AWARD-10	A3	PLACEBO	24	arm, events	0 / 140		R0020348:p1
NCT00393718	A1	LIRA_SC	52	arm, events	0 / 272		R0022766:Results
NCT00393718	A2	GLIBENCLAMIDE	52	arm, events	0 / 139		R0022766:Results
EGO	A1+A2+A3	DULA_SC	16	arm, events	0 / 196	arms_combined	registry:outcomes
EGO	A4	PLACEBO	16	arm, events	0 / 66		registry:outcomes
NCT00765817	A1	EXEN_SC	30	arm, events	0 / 138		R0027069:Table 3
NCT00765817	A2	PLACEBO	30	arm, events	1 / 123		R0027069:Table 3
NCT01029886	A1	EXENER_SC	26	arm, events	0 / 461		R0016299:Results
NCT01029886	A2	LIRA_SC	26	arm, events	0 / 451		R0016299:Results
SUSTAIN 11	A1	SEMA_SC	52	arm, events	4 / 874		R0022346:Table 2
SUSTAIN 11	A2	INS_ASPART	52	arm, events	6 / 874		R0022346:Table 2
NCT00791479	A1+A2+A3+A4	DULA_SC	12	arm, events	0 / 132	arms_combined	registry:outcomes
NCT00791479	A6	PLACEBO	12	arm, events	0 / 32		registry:outcomes
REMODEL	A1	SEMA_SC	57	arm, events	0 / 71		R0007381:Extended Data Table 5
REMODEL	A2	PLACEBO	57	arm, events	0 / 35		R0007381:Extended Data Table 5
NCT00637273	A1	EXENER_SC	26	arm, events	0 / 170		R0026900:Research design and methods
NCT00637273	A2	SITAGLIPTIN	26	arm, events	0 / 172		R0026900:Research design and methods
NCT00637273	A3	PIOGLITAZONE	26	arm, events	0 / 172		R0026900:Research design and methods
NCT00976937	A1	LIXI_SC	24	arm, events	0 / 158		R0012687:Table 2
NCT00976937	A2	SITAGLIPTIN	24	arm, events	0 / 161		R0012687:Table 2
NCT00516074	A1	EXEN_SC	12	arm, events	0 / 28		R0019195:Results
NCT00516074	A2	PLACEBO	12	arm, events	0 / 26		R0019195:Results
NCT00082407	A1	EXEN_SC	52	arm, events	0 / 255		R0025791:p6
NCT00082407	A2	INS_PREMIX	52	arm, events	0 / 250		R0025791:p6
AWARD-9	A1	DULA_SC	28	arm, events	1 / 150		R0024573:Results
AWARD-9	A2	PLACEBO	28	arm, events	0 / 150	count_from_percent	registry:outcomes
SUSTAIN 9	A1	SEMA_SC	36	arm, events	1 / 151		R0021710:Table 2
SUSTAIN 9	A2	PLACEBO	36	arm, events	0 / 151		R0021710:Table 2
GETGOAL-L-ASIA	A1	LIXI_SC	24	arm, events	0 / 154		R0022626:Results
GETGOAL-L-ASIA	A2	PLACEBO	24	arm, events	0 / 157		R0022626:Results
GETGOAL-S	A1	PLACEBO	120	arm, events	1 / 286		registry:outcomes
GETGOAL-S	A2	LIXI_SC	120	arm, events	2 / 573		registry:outcomes
LIRA-PRIME	A1	LIRA_SC	104	arm, events	1 / 996		R0022482:Supplement Table S5
LIRA-PRIME	A2	OTHER_ACTIVE_investigator_choice_oral_drug	104	arm, events	6 / 995		R0022482:Supplement Table S5
PIONEER 12	A1+A2+A3	SEMA_PO	31	arm, events	0 / 1,082	arms_combined	R0019776:Table 3
PIONEER 12	A4	SITAGLIPTIN	31	arm, events	0 / 359		R0019776:Table 3
NCT03596450	A1	SEMA_SC	104.36	arm, events	1 / 644		registry:outcomes
NCT03596450	A2	STANDARD_CARE	104.36	arm, events	1 / 634		registry:outcomes
NCT06589765	A1+A2+A3	SAFIGL_PO	52	arm, events	0 / 608	arms_combined	R0029347:Table 3
NCT06589765	A4	DAPAGLIFLOZIN	52	arm, events	0 / 202		R0029347:Table 3
NCT00960661	A1	EXEN_SC	30	arm, events	2 / 316		R0016788:Results
NCT00960661	A2	INS_LISPRO	30	arm, events	7 / 321		R0016788:Results
PREVAIL	A1	STANDARD_CARE	20	arm, events	0 / 33		R0010144:Supplementary Table 1
PREVAIL	A2	INS_LISPRO	20	arm, events	0 / 35		R0010144:Supplementary Table 1
PREVAIL	A3	EXEN_SC	20	arm, events	0 / 35		R0010144:Supplementary Table 1
NCT02229383	A1	EXENER_SC	38	arm, events	0 / 233		R0014763:Table 3
NCT02229383	A2	PLACEBO	38	arm, events	0 / 231		R0014763:Table 3
NCT00577824	A1	PLACEBO	24	arm, events	0 / 36		R0018881:Results
NCT00577824	A2+A3	EXEN_SC	24	arm, events	0 / 145	arms_combined	R0018881:Results
NCT01149421	A1+A2	DULA_SC	26	arm, events	0 / 505	arms_combined	registry:outcomes
NCT01149421	A3	PLACEBO	26	arm, events	0 / 250		registry:outcomes
NCT01558271	A1	DULA_SC	52	arm, events	0 / 281		R0011754:Results
NCT01558271	A2	LIRA_SC	52	arm, events	0 / 141		R0011754:Results
NCT00849017	A1	PLACEBO	52	arm, events	0 / 105		R0022386:Table 2
NCT00849017	A2+A3	ALBI_SC	52	arm, events	0 / 204	arms_combined	R0022386:Table 2
NCT00395746	A1+A2	LIRA_SC	52	arm, events	0 / 178	arms_combined	R0022802:Results
NCT00395746	A3	PLACEBO	52	arm, events	0 / 89		R0022802:Results
GRADE	A1	INS_GLARGINE	386.13	arm, events	10 / 1,263		R0020895:Table 2
GRADE	A2	GLIMEPIRIDE	386.13	arm, events	16 / 1,254		R0020895:Table 2
GRADE	A3	LIRA_SC	386.13	arm, events	6 / 1,262		R0020895:Table 2
GRADE	A4	SITAGLIPTIN	386.13	arm, events	4 / 1,268		R0020895:Table 2
NCT05759897	A1	PLACEBO	16	arm, events	0 / 39	printed_denominator	R0002101:Table 3
NCT05759897	A2+A3+A4+A5	SAFIGL_PO	16	arm, events	0 / 155	printed_denominator;arms_combined	R0002101:Table 3
SUSTAIN™1	A1+A2	SEMA_SC	35	arm, events	0 / 259	arms_combined	R0021710:Table 2
SUSTAIN™1	A3	PLACEBO	35	arm, events	0 / 129		R0021710:Table 2
GetGoal-O	A1	LIXI_SC	24.43	arm, events	1 / 176	count_from_percent	registry:outcomes
GetGoal-O	A2	PLACEBO	24.43	arm, events	0 / 174	count_from_percent	registry:outcomes
NCT01617434	A1	LIRA_SC	27	arm, events	0 / 226		R0026247:Results
NCT01617434	A2	PLACEBO	27	arm, events	0 / 225		R0026247:Results
LIRA-Ramadan™	A1	LIRA_SC	30	arm, events	0 / 172		R0025756:Results
LIRA-Ramadan™	A2	OTHER_ACTIVE_sulfonylurea	30	arm, events	0 / 171		R0025756:Results
NCT02200991	A1	LIXI_SC	4.43	arm, events	0 / 69		R0024589:Table 3
NCT02200991	A2	SITAGLIPTIN	4.43	arm, events	0 / 67		R0024589:Table 3
AWARD-CHN1	A1+A2	DULA_SC	26	arm, events	0 / 492	arms_combined	R0014229:Table 2
AWARD-CHN1	A3	GLIMEPIRIDE	26	arm, events	0 / 245		R0014229:Table 2
AWARD-8	A1	DULA_SC	24	arm, events	0 / 240		R0016038:Table 3
AWARD-8	A2	PLACEBO	24	arm, events	0 / 60		R0016038:Table 3
NCT02465515	A1	PLACEBO	140.89	arm, events	55 / 4,732		registry:outcomes
NCT02465515	A2	ALBI_SC	140.89	arm, events	31 / 4,731		registry:outcomes
LIRA-SWITCH™	A1	LIRA_SC	27	arm, events	0 / 203		R0025720:Table 1
LIRA-SWITCH™	A2	SITAGLIPTIN	27	arm, events	0 / 204		R0025720:Table 1
NCT02449603	A1	EXEN_SC	16	arm, events	0 / 52	printed_denominator	R0023224:Abstract
NCT02449603	A2	INS_PREMIX	16	arm, events	0 / 52	printed_denominator	R0023224:Abstract
DURATION-NEO-2	A1	EXENER_SC	28	arm, events	0 / 182		R0010641:Table 3
DURATION-NEO-2	A2	SITAGLIPTIN	28	arm, events	0 / 122		R0010641:Table 3
DURATION-NEO-2	A3	PLACEBO	28	arm, events	0 / 61		R0010641:Table 3
NCT05514535	A1	SEMA_SC	45	arm, events	4 / 288		R0015842:Table 2
NCT05514535	A2	INS_GLARGINE	45	arm, events	11 / 285		R0015842:Table 2
AWARD-6	A1	DULA_SC	26	arm, events	0 / 299	count_from_percent	registry:outcomes
AWARD-6	A2	LIRA_SC	26	arm, events	0 / 300	count_from_percent	registry:outcomes
GetGoal-M-Asia	A1	PLACEBO	24	arm, events	0 / 195		registry:outcomes
GetGoal-M-Asia	A2	LIXI_SC	24	arm, events	0 / 196		registry:outcomes
NCT03985293	A1	PLACEBO	20	arm, events	0 / 66		R0006095:Supplement eTable 1
NCT03985293	A2+A3+A4+A5+A6	DANU_PO	20	arm, events	0 / 346	arms_combined	R0006095:Supplement eTable 1
NCT01191268	A1+A2	DULA_SC	52	arm, events	15 / 588	arms_combined	registry:outcomes
NCT01191268	A3	INS_GLARGINE	52	arm, events	14 / 296		registry:outcomes
LixiLan-O	A1	IGLARLIXI_SC	30.14	arm, events	0 / 469		R0014829:Table 3
LixiLan-O	A2	INS_GLARGINE	30.14	arm, events	1 / 467		R0014829:Table 3
LixiLan-O	A3	LIXI_SC	30.14	arm, events	0 / 234		R0014829:Table 3
GETGOAL-P	A1	PLACEBO	132	arm, events	0 / 161		registry:outcomes
GETGOAL-P	A2	LIXI_SC	132	arm, events	0 / 323		registry:outcomes
NCT04504396	A1	VISEPE_SC	24	arm, events	0 / 310		R0009432:Table 3
NCT04504396	A2	PLACEBO	24	arm, events	0 / 310		R0009432:Table 3
NCT00877890	A1	EXENER_SC	24	arm, events	0 / 129		registry:outcomes
NCT00877890	A2	EXEN_SC	24	arm, events	0 / 125		registry:outcomes
SUSTAIN	A1+A2	SEMA_SC	35	arm, events	0 / 578	arms_combined	R0014802:Results
SUSTAIN	A3	SITAGLIPTIN	35	arm, events	0 / 290		R0014802:Results
NCT00360334	A1	EXEN_SC	26	arm, events	5 / 118		R0024925:Table 3
NCT00360334	A2	INS_GLARGINE	26	arm, events	6 / 117		R0024925:Table 3
NCT01003184	A1	EXENER_SC	26	arm, events	0 / 111		R0027663:Table 2
NCT01003184	A2	INS_DETEMIR	26	arm, events	0 / 111		R0027663:Table 2
SOLID-DKD	A1+A2	HRS7535_PO	18	arm, events	0 / 187	arms_combined	R0004355:Table 2
SOLID-DKD	A3	PLACEBO	18	arm, events	0 / 94		R0004355:Table 2
AWARD-CHN2	A1+A2	DULA_SC	52	arm, events	0 / 515	arms_combined	R0023722:Table 2
AWARD-CHN2	A3	INS_GLARGINE	52	arm, events	0 / 259		R0023722:Table 2
LixiLan-L	A1	IGLARLIXI_SC	30	arm, events	4 / 367		R0014829:Table 3
LixiLan-L	A2	INS_GLARGINE	30	arm, events	1 / 369		R0014829:Table 3
GETGOAL-X	A1	LIXI_SC	116	arm, events	0 / 320		registry:outcomes
GETGOAL-X	A2	EXEN_SC	116	arm, events	0 / 319		registry:outcomes
NCT00299871	A1	PLACEBO	13.43	arm, events	0 / 109		R0021613:Results
NCT00299871	A2+A3+A4+A5+A6+A7+A8+A9	LIXI_SC	13.43	arm, events	0 / 433	arms_combined	R0021613:Results
SUSTAIN™	A1+A2	SEMA_SC	62	arm, events	0 / 480	arms_combined	R0025024:Results
SUSTAIN™	A3	OTHER_ACTIVE_additional_OAD	62	arm, events	0 / 121		R0025024:Results
LEAD-2	A1+A3	LIRA_SC	104	arm, events	0 / 484	arms_combined	registry:outcomes
LEAD-2	A4	GLIMEPIRIDE	104	arm, events	0 / 244		registry:outcomes
LEAD-2	A5	PLACEBO	104	arm, events	0 / 122		registry:outcomes
DUAL™ II China	A1	IDEGLIRA_SC	26	arm, events	2 / 302		R0012135:Supplement Table 6
DUAL™ II China	A2	INS_DEGLUDEC	26	arm, events	0 / 151		R0012135:Supplement Table 6
GETGOAL-F1	A1	PLACEBO	112	arm, events	0 / 160	printed_denominator	registry:outcomes
GETGOAL-F1	A2+A3	LIXI_SC	112	arm, events	0 / 322	arms_combined	registry:outcomes
NCT00460941	A1	PLACEBO	12	arm, events	0 / 32	printed_denominator	R0021258:Results
NCT00460941	A2+A3+A4	TASP_SC	12	arm, events	0 / 97	printed_denominator;arms_combined	R0021258:Results
NCT03322631	A1	PLACEBO	12	arm, events	0 / 9		R0021917:Results
NCT03322631	A2+A3+A4	TIRZ_SC	12	arm, events	0 / 39	arms_combined	R0021917:Results
NCT00744926	A1	PLACEBO	24	arm, events	0 / 123	printed_denominator	R0025346:Results
NCT00744926	A2+A3	TASP_SC	24	arm, events	0 / 245	printed_denominator;arms_combined	R0025346:Results
NCT00971659	A1	EXEN_SC	4	arm, events	0 / 16		R0027899:Results
NCT00971659	A2	SITAGLIPTIN	4	arm, events	0 / 16		R0027899:Results
NCT00971659	A3	STANDARD_CARE	4	arm, events	0 / 16		R0027899:Results
ELEGANT	A1	LIRA_SC	26	arm, events	0 / 26		R0025175:Results
ELEGANT	A2	STANDARD_CARE	26	arm, events	0 / 24		R0025175:Results
NCT01126580	A1+A2	DULA_SC	52	arm, events	0 / 539	arms_combined	registry:outcomes
NCT01126580	A3	METFORMIN	52	arm, events	0 / 268		registry:outcomes
PIONEER 11	A1+A2+A3	SEMA_PO	31	arm, events	0 / 390	arms_combined	R0019663:Table 3
PIONEER 11	A4	PLACEBO	31	arm, events	0 / 131		R0019663:Table 3
SUSTAIN™ 5	A1+A2	SEMA_SC	35	arm, events	2 / 264	arms_combined	R0021710:Table 2
SUSTAIN™ 5	A3	PLACEBO	35	arm, events	1 / 133		R0021710:Table 2
SUSTAIN™ 2	A1+A2	SEMA_SC	56	arm, events	0 / 818	printed_denominator;arms_combined	R0021710:Table 2
SUSTAIN™ 2	A3	SITAGLIPTIN	56	arm, events	2 / 407	printed_denominator	R0021710:Table 2
NCT02229227	A1	ALBI_SC	26	arm, events	9 / 402		R0008089:Table 3
NCT02229227	A2	INS_LISPRO	26	arm, events	22 / 412		R0008089:Table 3
AGAC2	A1	PLACEBO	0.43	arm, events	0 / 21		R0020827:Supplementary Table 2
AGAC2	A2	EXEN_SC	0.43	arm, events	0 / 30		R0020827:Supplementary Table 2
NCT01632163	A1	LIXI_SC	24	arm, events	0 / 224		R0014725:Table 3
NCT01632163	A2	PLACEBO	24	arm, events	0 / 224		R0014725:Table 3
NCT00676338	A1	EXENER_SC	26	arm, events	0 / 248		R0027761:Results
NCT00676338	A2	METFORMIN	26	arm, events	0 / 246		R0027761:Results
NCT00676338	A3	PIOGLITAZONE	26	arm, events	0 / 163		R0027761:Results
NCT00676338	A4	SITAGLIPTIN	26	arm, events	0 / 163		R0027761:Results
LIXILAN JP-O1	A1	IGLARLIXI_SC	52.14	arm, events	0 / 161		R0015751:Table 3
LIXILAN JP-O1	A2	LIXI_SC	52.14	arm, events	0 / 160		R0015751:Table 3
GETGOAL-L	A1	PLACEBO	125	arm, events	1 / 167		registry:outcomes
GETGOAL-L	A2	LIXI_SC	125	arm, events	7 / 329		registry:outcomes
NCT02887625	A1	EXENER_SC	78.21	arm, events	0 / 129		R0026120:Supplementary Table 1
NCT02887625	A2	OTHER_ACTIVE_basal_bolus_insulin	78.21	arm, events	1 / 122		R0026120:Supplementary Table 1
NCT03550378	A1	COTA_SC	8.43	arm, events	0 / 21		R0019218:Results
NCT03550378	A2	PLACEBO	8.43	arm, events	0 / 20		R0019218:Results
AMPLITUDE-M	A1+A2+A3	EFPE_SC	56	arm, events	1 / 304	arms_combined	R0007136:Table 2
AMPLITUDE-M	A4	PLACEBO	56	arm, events	0 / 102		R0007136:Table 2
SUSTAIN™	A1+A2	SEMA_SC	35	arm, events	0 / 205	arms_combined	R0014736:Results
SUSTAIN™	A3	SITAGLIPTIN	35	arm, events	0 / 103		R0014736:Results
LEAD-5	A1	LIRA_SC	26	arm, events	5 / 232		R0027336:Results
LEAD-5	A2	PLACEBO	26	arm, events	0 / 115		R0027336:Results
LEAD-5	A3	INS_GLARGINE	26	arm, events	0 / 234		R0027336:Results
Lixilan-L-CN	A1	IGLARLIXI_SC	30	arm, events	2 / 212		R0014540:Supplement Table S4
Lixilan-L-CN	A2	INS_GLARGINE	30	arm, events	2 / 214		R0014540:Supplement Table S4
NCT05767255	A1	IDEGLIRA_SC	4	arm, events	0 / 32		R0007026:Table 4
NCT05767255	A2	OTHER_ACTIVE_basal_bolus_insulin	4	arm, events	10 / 33		R0007026:Table 4
NCT04998032	A1	EFSUBA_SC	24	arm, events	0 / 171		R0006975:Table 3
NCT04998032	A2	PLACEBO	24	arm, events	0 / 173		R0006975:Table 3
GETGOAL-M	A1+A2	LIXI_SC	76.43	arm, events	0 / 510	arms_combined	registry:outcomes
GETGOAL-M	A3	PLACEBO	76.43	arm, events	0 / 170	printed_denominator	registry:outcomes
NCT01425580	A1	LIRA_SC	18	arm, events	0 / 33		R0025885:Results
NCT01425580	A2	GLIMEPIRIDE	18	arm, events	0 / 29		R0025885:Results
NCT03311724	A1	PLACEBO	16	arm, events	0 / 26		R0010282:Table 2
NCT03311724	A2+A3+A4	TIRZ_SC	16	arm, events	0 / 85	arms_combined	R0010282:Table 2
NCT04466904	A2	MAZD_SC	20	arm, events	0 / 8		R0009340:Table 2
NCT04466904	A4	DULA_SC	20	arm, events	0 / 6	printed_denominator	R0009340:Table 2
NCT04466904	A5	PLACEBO	20	arm, events	0 / 12	printed_denominator	R0009340:Table 2
GETGOAL-MONO	A1	PLACEBO	12.43	arm, events	0 / 122	printed_denominator	R0022843:Results
GETGOAL-MONO	A2+A3	LIXI_SC	12.43	arm, events	0 / 239	arms_combined	R0022843:Results
NCT02113332	A1	LIRA_SC	24	arm, events	0 / 64		R0026157:Results
NCT02113332	A2	PLACEBO	24	arm, events	0 / 60		R0026157:Results
NCT00700817	A1+A2	LIRA_SC	52	arm, events	1 / 446	arms_combined	R0024199:Results
NCT00700817	A3	SITAGLIPTIN	52	arm, events	0 / 219		R0024199:Results
NCT03520972	A1	PLACEBO	12	arm, events	0 / 62		R0011873:Results
NCT03520972	A2+A3+A4	PEGYLA_SC	12	arm, events	0 / 189	arms_combined	R0011873:Results
S002928	A1	PLACEBO	24	arm, events	0 / 41		R0007034:Table 4
S002928	A2+A3	PEGLOX_SC	24	arm, events	0 / 82	arms_combined	R0007034:Table 4
S002951	A1	PEGLOX_SC	16	arm, events	0 / 104		R0007588:Table 3
S002951	A2	METFORMIN	16	arm, events	0 / 52		R0007588:Table 3
S002984	A1	PEGLOX_SC	24	arm, events	0 / 39		R0011969:Results
S002984	A2	INS_GLARGINE	24	arm, events	1 / 39		R0011969:Results
S003009	A1	PEGLOX_SC	24	arm, events	0 / 44		R0011381:Table 4
S003009	A2	DAPAGLIFLOZIN	24	arm, events	0 / 44		R0011381:Table 4
S003030	A1	EXEN_SC	52	arm, events	0 / 33		R0018574:Results
S003030	A2	INS_PREMIX	52	arm, events	0 / 33		R0018574:Results
S003047	A1+A2	LIXI_SC	6.57	arm, events	0 / 80	printed_denominator;arms_combined	R0016337:Results
S003047	A3	PLACEBO	6.57	arm, events	0 / 40	printed_denominator	R0016337:Results
S003050	A1	METFORMIN	12	arm, events	0 / 30		R0021314:Results
S003050	A2	DULA_SC	12	arm, events	0 / 30		R0021314:Results
S003058	A1	LIXI_SC	12	arm, events	0 / 23		R0024376:Results
S003058	A2	VILDAGLIPTIN	12	arm, events	0 / 25		R0024376:Results
S003070	A1	STANDARD_CARE	2	arm, events	0 / 30		R0024678:p5
S003070	A2	LIRA_SC	2	arm, events	0 / 30		R0024678:p5
S003071	A1	LIRA_SC	24	arm, events	0 / 50		R0023696:Results
S003071	A2	SITAGLIPTIN	24	arm, events	0 / 49		R0023696:Results
S003072	A1	VILDAGLIPTIN	14	arm, events	0 / 62		R0023470:Results
S003072	A2	LIRA_SC	14	arm, events	0 / 60		R0023470:Results
S003079	A1	EXEN_SC	5	arm, events	0 / 18		R0025923:Results
S003079	A2	STANDARD_CARE	5	arm, events	0 / 18		R0025923:Results
S003094	A1	LIRA_SC	12	arm, events	0 / 42		R0026794:Results
S003094	A2	OTHER_ACTIVE_insulin_dose_increase	12	arm, events	2 / 42		R0026794:Results
S003437	A1	METFORMIN	24	arm, events	0 / 60		R0053478:Results
S003437	A2+A3	SEMA_SC	24	arm, events	0 / 120	arms_combined	R0053478:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab